BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072. [PMID: 18565894 DOI: 10.1200/jco.2007.15.4377] [Cited by in Crossref: 2939] [Cited by in F6Publishing: 3212] [Article Influence: 209.9] [Reference Citation Analysis]
Number Citing Articles
1 Matsuno K, Miyamoto H, Kitada H, Yoshimatsu S, Tamura F, Sakurai K, Fukubayashi K, Shono T, Setoyama H, Matsuyama T, Suko S, Narita R, Honda M, Tateyama M, Naoe H, Morinaga J, Tanaka Y, Gushima R. Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study. DEN Open 2023;3. [DOI: 10.1002/deo2.163] [Reference Citation Analysis]
2 Rinke A, Denzer UW. Kolorektale NEN (ohne Fernmetastasen). Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_48] [Reference Citation Analysis]
3 Marcal LP, Chuang HH, Tran Cao HS, Halperin DM. Pancreatic Neuroendocrine Tumors. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00014-8] [Reference Citation Analysis]
4 Bartsch DK, Maurer E, Holzer K. Neuroendokrine Neoplasien des Jejunums und Ileums (SI-NEN). Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_46] [Reference Citation Analysis]
5 Morishita S, Yoshida S, Kamatani Y, Suzuhigashi S, Kitou M, Nasu T. Primary grade 2 neuroendocrine tumor of the ileal mesentery: a case report. surg case rep 2022;8:146. [DOI: 10.1186/s40792-022-01482-x] [Reference Citation Analysis]
6 Gaspar TB, Lopes JM, Soares P, Vinagre J. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 2022;29:R191-R208. [DOI: 10.1530/erc-22-0166] [Reference Citation Analysis]
7 Yang H, Liu T, Li M, Fang Z, Luo L. Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors? American Journal of Clinical Oncology 2022;45:506-513. [DOI: 10.1097/coc.0000000000000958] [Reference Citation Analysis]
8 Kong G, Hicks RJ. PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable? Current Opinion in Pharmacology 2022;67:102293. [DOI: 10.1016/j.coph.2022.102293] [Reference Citation Analysis]
9 Luo PP, Ou XL. Endoscopic mucosal dissection for multiple rectal carcinoids: A case report. Shijie Huaren Xiaohua Zazhi 2022; 30(22): 1004-1008 [DOI: 10.11569/wcjd.v30.i22.1004] [Reference Citation Analysis]
10 Ma X, Ding Y, Li W, Li Q, Yang H. Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1061065] [Reference Citation Analysis]
11 Lan X, Fazio N, Abdel-rahman O. Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms. Metabolites 2022;12:1150. [DOI: 10.3390/metabo12111150] [Reference Citation Analysis]
12 Kurita Y, Kobayashi N, Hara K, Mizuno N, Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Kubota K, Nakajima A, Ichikawa Y. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers 2022;14:5669. [DOI: 10.3390/cancers14225669] [Reference Citation Analysis]
13 Исянгулова АЗ, Гордиев МГ. Молекулярный профиль нейроэндокринных опухолей. Zlokač opuholi 2022;12:9-16. [DOI: 10.18027/2224-5057-2022-12-3s1-9-16] [Reference Citation Analysis]
14 Zhang R, Guo Y, Wang Y, Hu L, Fang C, Yang Y, Yang X, Chen L, Chen J, Wang W, Sun X. Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system. Cancer Medicine 2022. [DOI: 10.1002/cam4.5437] [Reference Citation Analysis]
15 Song L, Cao Y, Li J, Lu M, Tang L. Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.947998] [Reference Citation Analysis]
16 Kosmala A, Serfling SE, Schlötelburg W, Lindner T, Michalski K, Schirbel A, Higuchi T, Hartrampf PE, Buck AK, Weich A, Werner RA. Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004480] [Reference Citation Analysis]
17 Liang W, Xu X, Liu Y, Cui J, Gao Y, Wang C, Zhuang Z, Zhang K, Xi H, Cai A, Wei B, Chen L. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis. World J Surg Onc 2022;20:356. [DOI: 10.1186/s12957-022-02822-9] [Reference Citation Analysis]
18 Lin J, Li X, Ding X, Chen Z, Wu Y, Zhao K. Developing a competing risk nomogram that predicts the survival of patients with a primary hepatic neuroendocrine tumor. Front Med 2022;9. [DOI: 10.3389/fmed.2022.960235] [Reference Citation Analysis]
19 O’connor JM, Ángel M, Pesce V, Méndez G, Bestani C, Marmisolle F, Giacomi N, Belli S, Domenichini E, Zamora V, Cabanne A, Parma P, Roca E. Índice de proliferación (KI-67) en pacientes con tumores neuroendocrinos gastroenteropancreáticos. RevOnco 2022;25. [DOI: 10.56969/oc.v25i1.25] [Reference Citation Analysis]
20 Gebauer N, Ziehm M, Gebauer J, Riecke A, Meyhöfer S, Kulemann B, von Bubnoff N, Steinestel K, Bauer A, Witte HM. The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System. Cancers 2022;14:5465. [DOI: 10.3390/cancers14215465] [Reference Citation Analysis]
21 Tian R, Xie Q, Yu F, Du C, Yao X, Zang S, Zhang C, Zhang P, Shao G, Yang Z, Wang F, Yu J. Detection of Bone Metastases by 68Ga-DOTA-SSAs and 18F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media & Molecular Imaging 2022;2022:1-11. [DOI: 10.1155/2022/1750132] [Reference Citation Analysis]
22 Hayoune A, Kharouaa B, Thouil A, Kouismi H. Atypical Bronchial Carcinoid Tumor Revealed by Liver Biopsy. Cureus 2022. [DOI: 10.7759/cureus.31104] [Reference Citation Analysis]
23 Khan IA, Saraya A. Circulating MicroRNAs as Noninvasive Diagnostic and Prognostic Biomarkers in Pancreatic Cancer: A Review. J Gastrointest Canc 2022. [DOI: 10.1007/s12029-022-00877-1] [Reference Citation Analysis]
24 Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, Faggiano A, Colao A. Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target. Metabolites 2022;12:1057. [DOI: 10.3390/metabo12111057] [Reference Citation Analysis]
25 Rösner E, Kaemmerer D, Sänger J, Lupp A. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Transl Oncol 2022;25:101526. [PMID: 36067541 DOI: 10.1016/j.tranon.2022.101526] [Reference Citation Analysis]
26 Ye Z, Chen H, Ji S, Hu Y, Lou X, Zhang W, Jing D, Fan G, Zhang Y, Chen X, Zhuo Q, Chen J, Xu X, Yu X, Xu J, Qin Y, Gao H. MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. ABBS 2022. [DOI: 10.3724/abbs.2022162] [Reference Citation Analysis]
27 van Amstel P, Mahieu A, Bakx R, de Vries R, Raphael MF, Derikx JP, van Heurn LE, Gorter RR. Management and outcome of high-risk neuroendocrine tumors of the appendix in children; A systematic review. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.10.021] [Reference Citation Analysis]
28 Takamoto T, Nara S, Ban D, Mizui T, Murase Y, Esaki M, Shimada K. Chronological improvement of pancreatectomy for resectable but advanced pancreatic neuroendocrine neoplasms. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.11.004] [Reference Citation Analysis]
29 Martin S, Iravani A, Shetty AS, Zulfiqar M, Morani A, Yano M, Bhosale PR, Itani M. Neuroendocrine neoplasm imaging: protocols by site of origin. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03713-z] [Reference Citation Analysis]
30 Kawasaki K, Rekhtman N, Quintanal-villalonga Á, Rudin CM. Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nat Rev Clin Oncol 2022. [DOI: 10.1038/s41571-022-00696-0] [Reference Citation Analysis]
31 Raderer M, Kiesewetter B. The NET G3 enigma: dealing with a “new” entity. memo 2022. [DOI: 10.1007/s12254-022-00848-z] [Reference Citation Analysis]
32 Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm083.pub2] [Reference Citation Analysis]
33 Budek M, Nuszkiewicz J, Piórkowska A, Czuczejko J, Szewczyk-Golec K. Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomedicines 2022;10:2660. [PMID: 36289922 DOI: 10.3390/biomedicines10102660] [Reference Citation Analysis]
34 Yagi K, Ono H, Kudo A, Kinowaki Y, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Tanaka S, Tanabe M. Inactivation of MGMT is Associated With the Efficacy of Streptozocin and High-grade Pancreatic Neuroendocrine Neoplasms.. [DOI: 10.21203/rs.3.rs-2161835/v1] [Reference Citation Analysis]
35 Huang XT, Xie JZ, Cai JP, Fang P, Huang CS, Chen W, Liang LJ, Yin XY. Values of spleen-preserving distal pancreatectomy in well-differentiated non-functioning pancreatic neuroendocrine tumors: a comparative study. Gastroenterol Rep (Oxf) 2022;10:goac056. [PMID: 36263393 DOI: 10.1093/gastro/goac056] [Reference Citation Analysis]
36 Chen YT, Huang PY, Wang JY, Lee YC, Chai CY. An innovative diagnosis in gastrointestinal neuroendocrine neoplasms using Wax-Physisorption-Kinetics-based FTIR Imaging. Sci Rep 2022;12:17168. [PMID: 36229592 DOI: 10.1038/s41598-022-22221-0] [Reference Citation Analysis]
37 La Salvia A, Carletti R, Verrico M, Feola T, Puliani G, Bassi M, Sesti F, Pernazza A, Mazzilli R, Lamberti G, Siciliani A, Mancini M, Manai C, Venuta F, Ibrahim M, Tomao S, D'Amati G, Di Gioia C, Giannetta E, Cappuzzo F, Faggiano A. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma. J Clin Med 2022;11:5958. [PMID: 36233825 DOI: 10.3390/jcm11195958] [Reference Citation Analysis]
38 Souquet P, Girard N, Gérinière L, Odier L, Do Cao C, Dansin E, Poté N, Darrason M. Néoplasies neuro-endocrines broncho-pulmonaires primitives : tumeurs carcinoïdes et carcinomes neuro-endocrines à grandes cellules. Revue des Maladies Respiratoires Actualités 2022;14:2S277-2S286. [DOI: 10.1016/s1877-1203(22)00128-8] [Reference Citation Analysis]
39 Senapathi SH, Keller HR, Morada A, Bertsch D, Cagir B. Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.09.053] [Reference Citation Analysis]
40 El Bakouri A, El wassi A, Eddaoudi Y, Bouali M, El Hattabi K, Bensardi F, Fadil A. Fortuitous discovery of an early neuroendocrine tumor during appendicular peritonitis. Annals of Medicine and Surgery 2022;82:104735. [DOI: 10.1016/j.amsu.2022.104735] [Reference Citation Analysis]
41 Shen X, Wang X, Lu X, Zhao Y, Guan W. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation. Front Oncol 2022;12:967071. [DOI: 10.3389/fonc.2022.967071] [Reference Citation Analysis]
42 Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Ragni A, Zanata I, Colao A, Faggiano A. What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature. JPM 2022;12:1553. [DOI: 10.3390/jpm12101553] [Reference Citation Analysis]
43 Gonzáles-Yovera JG, Roseboom PJ, Concepción-Zavaleta M, Gutiérrez-Córdova I, Plasencia-Dueñas E, Quispe-Flores M, Ramos-Yataco A, Alcalde-Loyola C, Massucco-Revoredo F, Paz-Ibarra J, Concepción-Urteaga L. Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. World J Methodol 2022; 12(5): 381-391 [DOI: 10.5662/wjm.v12.i5.381] [Reference Citation Analysis]
44 Romero Serrano SA, Baez Ariza EA, Pardo Gonzalez SY, Martínez Martínez S. Presentación polipoide de un tumor neuroendocrino: reporte de caso y revisión de la literatura. Rev colomb Gastroenterol 2022;37:325-329. [DOI: 10.22516/25007440.813] [Reference Citation Analysis]
45 Wang Q, Tan Y, Yang H, Zhang J, Lei X, Liu M, He L. Using radiomics to predict microvascular invasion in hepatocellular carcinoma based on multi-sequence gadoxetate disodium–enhanced MRI combined with clinical parameters.. [DOI: 10.21203/rs.3.rs-2055181/v1] [Reference Citation Analysis]
46 Iabichino G, Di Leo M, Arena M, Rubis Passoni GG, Morandi E, Turpini F, Viaggi P, Luigiano C, De Luca L. Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(34): 4943-4958 [DOI: 10.3748/wjg.v28.i34.4943] [Reference Citation Analysis]
47 Huang XT, Xie JZ, Huang CS, Li JH, Chen W, Liang LJ, Yin XY. Development and validation of nomogram to predict lymph node metastasis preoperatively in patients with pancreatic neuroendocrine tumor. HPB (Oxford) 2022:S1365-182X(22)01586-6. [PMID: 36127226 DOI: 10.1016/j.hpb.2022.08.015] [Reference Citation Analysis]
48 Nebuya S, Oe S, Harada Y, Takeuchi Y, Yoneda A, Koya Y, Miyagawa K, Honma Y, Shibata M, Harada M. A Case of Pancreatic Neuroendocrine Tumor G3 Which Responded Remarkably to Chemotherapy. J UOEH 2022;44:287-292. [DOI: 10.7888/juoeh.44.287] [Reference Citation Analysis]
49 Nießen A, Schimmack S, Lewosinska M, Hinz U, Bechtiger FA, Hackert T, Büchler MW, Strobel O. Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms. Surgery 2022. [DOI: 10.1016/j.surg.2022.08.020] [Reference Citation Analysis]
50 Kalantarhormozi M, Hassanzadeh S, Rekabpour SJ, Ravanbod MR, Jafari E, Amini A, Dadgar H, Mahmoudpour M, Nabipour I, Jokar N, Assadi M. Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment. World J Nucl Med 2022;21:215-221. [DOI: 10.1055/s-0042-1755412] [Reference Citation Analysis]
51 Ehms B, Kaemmerer D, Sänger J, Schulz S, Lupp A. Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61. Sci Rep 2022;12:14722. [PMID: 36042228 DOI: 10.1038/s41598-022-19014-w] [Reference Citation Analysis]
52 Yumoto S, Nakagawa S, Hayashi H, Ogawa D, Shiraishi Y, Sato H, Matsumoto T, Imai K, Yamashita Y, Baba H. Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival. Clin J Gastroenterol 2022. [DOI: 10.1007/s12328-022-01689-3] [Reference Citation Analysis]
53 Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 2022:oyac161. [PMID: 35983951 DOI: 10.1093/oncolo/oyac161] [Reference Citation Analysis]
54 Escobar KM, Vicente-villardon JL, Villacís Gonzalez RE, Castillo Cordova PH, Sánchez Rodríguez JM, De la Cruz-velez M, Siteneski A. Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador. Healthcare 2022;10:1569. [DOI: 10.3390/healthcare10081569] [Reference Citation Analysis]
55 Liu J, Pan X, Sun Y, Dong T, Hu X, Zhong H, Lu J, Yang D. Clinicopathological Features and Postoperative Survival Analysis of Gastric Carcinoma with Neuroendocrine Differentiation. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/4440098] [Reference Citation Analysis]
56 Cai XC, Wu SD. Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review. World J Clin Cases 2022; 10(23): 8212-8223 [DOI: 10.12998/wjcc.v10.i23.8212] [Reference Citation Analysis]
57 Agarwal P, Mohamed A. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Curr Treat Options Oncol 2022. [PMID: 35939200 DOI: 10.1007/s11864-022-00998-6] [Reference Citation Analysis]
58 Mäkinen N, Zhou M, Zhang Z, Kasai Y, Perez E, Kim GE, Thirlwell C, Nakakura E, Meyerson M. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors. Genome Med 2022;14:82. [PMID: 35922826 DOI: 10.1186/s13073-022-01083-1] [Reference Citation Analysis]
59 Jia J, Zeng X, Li C, Yang L, Huang Y, Tong X, Jiang Q, Zhang P, Tao K. A Combination of Preoperative Computed Tomography-Defined Sarcopenia and Systemic Inflammation on Survival in Patients with Poorly Differentiated Neuroendocrine Neoplasms Following Radical Resection. Nutr Cancer 2022;:1-11. [PMID: 35920394 DOI: 10.1080/01635581.2022.2102660] [Reference Citation Analysis]
60 Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of Radioembolization in Metastatic Neuroendocrine Tumors. Cardiovasc Intervent Radiol 2022. [PMID: 35918431 DOI: 10.1007/s00270-022-03206-y] [Reference Citation Analysis]
61 Greenberg JA, Ivanov NA, Egan CE, Lee YJ, Zarnegar R, Fahey TJ 3rd, Finnerty BM, Min IM. Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2022. [PMID: 35915373 DOI: 10.1007/s11605-022-05345-6] [Reference Citation Analysis]
62 Abdel-rahman O, Ghosh S. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Nondigestive, Nonpulmonary Primary. Pancreas 2022;51:769-773. [DOI: 10.1097/mpa.0000000000002108] [Reference Citation Analysis]
63 Fernandes CJ, Leung G, Eads JR, Katona BW. Gastroenteropancreatic Neuroendocrine Tumors. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2022.06.002] [Reference Citation Analysis]
64 Živojinov M, Panić Ž, Ilić A, Ilić Sabo J, Vasilijević M, Lakić T. Morphological and immunohistochemical features of neuroendocrine neoplasms in gastroenteropancreatic tract. Arab J Gastroenterol 2022:S1687-1979(22)00037-5. [PMID: 35927198 DOI: 10.1016/j.ajg.2022.05.005] [Reference Citation Analysis]
65 Lamberti G, La Salvia A. Neuroendocrine Tumors: Challenges and Future Perspectives. JCM 2022;11:4351. [DOI: 10.3390/jcm11154351] [Reference Citation Analysis]
66 Bartsch DK, Windel S, Kanngießer V, Jesinghaus M, Holzer K, Rinke A, Maurer E. Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:3610. [PMID: 35892869 DOI: 10.3390/cancers14153610] [Reference Citation Analysis]
67 Heaphy CM, Singhi AD. The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). Hum Pathol 2022:S0046-8177(22)00189-7. [PMID: 35872157 DOI: 10.1016/j.humpath.2022.07.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Wang Y, Huang B, Fu Q, Wang J, Ye M, Hu M, Qu K, Liu K, Hu X, Wei S, Sun K, Xiao W, Zhang B, Li H, Li J, Zhang Q, Liang T. Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade. Ann Surg Oncol 2022. [PMID: 35849293 DOI: 10.1245/s10434-022-12107-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Ren SJ, Wang X, Ke NW, Tan QQ, Yang F, Yao WQ, Tan CL, Liu XB. Clinicopathological features and long-term prognosis of purely cystic pancreatic neuroendocrine tumors: A single center experience. Asian J Surg 2022:S1015-9584(22)00975-7. [PMID: 35850904 DOI: 10.1016/j.asjsur.2022.07.029] [Reference Citation Analysis]
70 Ramdhani K, Braat AJAT. The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers 2022;14:3415. [DOI: 10.3390/cancers14143415] [Reference Citation Analysis]
71 de Lima BAM, da Silva RG, Carroll C, Vilhena B, Perez C, Felix R, Carneiro M, Neto LM, Vaisman F, Corbo R, Pujatti PB, Bulzico D. Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. Endocrine 2022. [PMID: 35829985 DOI: 10.1007/s12020-022-03133-5] [Reference Citation Analysis]
72 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
73 Ye J, Wu H, Li J, Liu C. Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score–Based Inverse Probability of Treatment Weighting. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.890564] [Reference Citation Analysis]
74 Si Y, Huang C, Yuan J, Zhang X, He Q, Lin Z, He L, Liu Z, Teekaraman Y. Analysis of Prognostic Risk Factors of Endoscopic Submucosal Dissection (ESD) and Curative Resection of Gastrointestinal Neuroendocrine Neoplasms. Contrast Media & Molecular Imaging 2022;2022:1-7. [DOI: 10.1155/2022/5248256] [Reference Citation Analysis]
75 Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, Palo L, Giordano A, Incoronato M, Vitale M, Mian C, Di Biase I, Cristiano S, Narciso V, Cantile M, Di Mauro A, Tatangelo F, Tafuto S, Modica R, Pivonello C, Salvatore M, Colao A, Weisz A, Tarallo R. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03511-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, Havekes B, Hofland J, Kerkhofs TMA, Klümpen HJ, Latten-Jansen LM, Speel EM, Verburg FA, Walenkamp AME, Geurts SME, de Vos-Geelen J. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer 2022;172:252-63. [PMID: 35803176 DOI: 10.1016/j.ejca.2022.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Froehlich MH, Shih MC, Shehee L, Kompelli AR, Aylward A, Nguyen SA, Kaczmar JM, Nathan CA, Day T, Neskey DM. Systematic review of neuroendocrine carcinomas of the oropharynx. Head Neck 2022;44:1725-36. [PMID: 35437851 DOI: 10.1002/hed.27055] [Reference Citation Analysis]
78 Gnanasegaran G, Agrawal K, Wan S. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies. PET Clin 2022;17:369-88. [PMID: 35717098 DOI: 10.1016/j.cpet.2022.03.007] [Reference Citation Analysis]
79 Nadalin S, Peters M, Königsrainer A. Lebermetastasen neuroendokriner Tumoren. Chirurgie 2022;93:659-666. [DOI: 10.1007/s00104-022-01656-1] [Reference Citation Analysis]
80 Molasy B, Zemła P, Mrowiec S, Grudzińska E, Kuśnierz K. Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors. TCRM 2022;Volume 18:745-52. [DOI: 10.2147/tcrm.s361332] [Reference Citation Analysis]
81 Rossi RE, Massironi S. The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. JCM 2022;11:3794. [DOI: 10.3390/jcm11133794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Nakao Y, Hayashi H, Yamashita YI, Takashi O, Matsumura K, Uemura N, Kitamura F, Itoyama R, Yusa T, Taki K, Miyata T, Higashi T, Nakagawa S, Okabe H, Imai K, Baba H. Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms. World J Clin Oncol 2022; 13(6): 520-528 [DOI: 10.5306/wjco.v13.i6.520] [Reference Citation Analysis]
83 Saha S, Ghosh P, Mukherjee G, Roy A. Metastatic Primary Neuroendocrine Tumor of Ovary—A Rare Presentation. Indian J Radiol Imaging. [DOI: 10.1055/s-0042-1744233] [Reference Citation Analysis]
84 Gopan A, Sen Sarma M, Har B, Singh RK, Agrawal V, Yachha SK. An unusual cause of obstructive jaundice in childhood: Intra-choledochal malignant neuroendocrine tumour. J Paediatr Child Health 2022. [PMID: 35716114 DOI: 10.1111/jpc.16060] [Reference Citation Analysis]
85 Xu A, Suz P, Reljic T, Are AC, Kumar A, Powers B, Strosberg J, Denbo JW, Fleming JB, Anaya DA. Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:2966. [PMID: 35740631 DOI: 10.3390/cancers14122966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Kurita Y, Kobayashi N, Hara K, Mizuno N, Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Sato T, Hosono K, Kato S, Kessoku T, Endo I, Shimizu Y, Kubota K, Nakajima A, Ichikawa Y, Niwa Y. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Intern Med 2022. [PMID: 35705270 DOI: 10.2169/internalmedicine.9416-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Wang P, Chen E, Xie M, Xu W, Ou C, Zhou Z, Niu Y, Song W, Ni Q, Zhu J. The Number of Lymph Nodes Examined is Associated with Survival Outcomes of Neuroendocrine Tumors of the Jejunum and Ileum (siNET): Development and Validation of a Prognostic Model Based on SEER Database. J Gastrointest Surg 2022. [PMID: 35689008 DOI: 10.1007/s11605-022-05359-0] [Reference Citation Analysis]
88 Chen Y, Zhang J, Zhou M, Guo C, Li S. Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis. Orphanet J Rare Dis 2022;17:215. [PMID: 35668481 DOI: 10.1186/s13023-022-02366-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhu Z. A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2022. [PMID: 35657429 DOI: 10.1007/s00259-022-05852-3] [Reference Citation Analysis]
90 Shi H, Wang C, Wu J, Qin B, Jiang J, Liu N, Song Y, Qin Y, Ma S. Underwater endoscopic mucosal resection for rectal neuroendocrine tumors (with videos): a single center retrospective study. BMC Gastroenterol 2022;22:276. [PMID: 35655173 DOI: 10.1186/s12876-022-02350-6] [Reference Citation Analysis]
91 Luo X, Yang M, Tian B, Liu X, Duan K, Zhang Y. Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results. J Clin Med 2022;11:3176. [PMID: 35683561 DOI: 10.3390/jcm11113176] [Reference Citation Analysis]
92 Takeda Y, Kobayashi N, Kessoku T, Okubo N, Suzuki A, Tokuhisa M, Miwa H, Udaka N, Ichikawa Y. Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. Clin J Gastroenterol 2022. [PMID: 35653037 DOI: 10.1007/s12328-022-01645-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Adv Ther 2022;39:2731-48. [PMID: 35419649 DOI: 10.1007/s12325-022-02103-7] [Reference Citation Analysis]
94 Bösch F, Ghadimi M, Angele MK. Personalisierte Resektionsverfahren bei neuroendokrinen Neoplasien des Pankreas. Zentralbl Chir 2022;147:264-269. [DOI: 10.1055/a-1823-1275] [Reference Citation Analysis]
95 Baruah U, Tak A, Kakoti L, Barmon D. Carcinoid ovary with synchronous carcinoid tumour of the appendix: report of a rare occurrence with review of literature. BMJ Case Rep 2022;15:e248869. [DOI: 10.1136/bcr-2022-248869] [Reference Citation Analysis]
96 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Radiopraxis 2022;15:E35-E47. [DOI: 10.1055/a-1714-2040] [Reference Citation Analysis]
97 Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clin Nucl Med 2022;47:503-11. [PMID: 35507433 DOI: 10.1097/RLU.0000000000004182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Liu SL, Luo M, Gou HX, Yang XL, He K. Castleman disease of the pancreas mimicking pancreatic malignancy on 68Ga-DOTATATE and 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report. World J Gastrointest Surg 2022; 14(5): 514-520 [DOI: 10.4240/wjgs.v14.i5.514] [Reference Citation Analysis]
99 Que QY, Zhang LC, Bao JQ, Ling SB, Xu X. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 397-408 [DOI: 10.4240/wjgs.v14.i5.397] [Reference Citation Analysis]
100 Evans LM, Geenen KR, O'Shea A, Hedgire SS, Ferrone CR, Thiele EA. Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes. Am J Med Genet A 2022. [PMID: 35612824 DOI: 10.1002/ajmg.a.62850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Chiappetta M, Tabacco D, Sassorossi C, Sperduti I, Cusumano G, Terminella A, Fournel L, Alifano M, Guerrera F, Filosso PL, Nicosia S, Gallina F, Facciolo F, Margaritora S, Lococo F. External Validation of a Prognostic Score for Survival in Lung Carcinoids. Cancers (Basel) 2022;14:2601. [PMID: 35681581 DOI: 10.3390/cancers14112601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Nießen A, Bechtiger FA, Hinz U, Lewosinska M, Billmann F, Hackert T, Büchler MW, Schimmack S. Enucleation Is a Feasible Procedure for Well-Differentiated pNEN-A Matched Pair Analysis. Cancers (Basel) 2022;14:2570. [PMID: 35626174 DOI: 10.3390/cancers14102570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Abdel-Rahman O, Ghosh S, Morrish D. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. J Endocrinol Invest 2022. [PMID: 35606667 DOI: 10.1007/s40618-022-01805-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Hiltunen N, Rintala J, Väyrynen JP, Böhm J, Karttunen TJ, Huhta H, Helminen O. Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors. Cancers 2022;14:2552. [DOI: 10.3390/cancers14102552] [Reference Citation Analysis]
105 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Zhang Z, Wang F, Li Z, Ye Z, Zhuo Q, Xu W, Liu W, Liu M, Fan G, Qin Y, Zhang Y, Chen X, Yu X, Xu X, Ji S. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. BMC Surg 2022;22:160. [PMID: 35538535 DOI: 10.1186/s12893-022-01595-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Massironi S, Rossi RE, Milanetto AC, Andreasi V, Campana D, Nappo G, Partelli S, Gallo C, Scaravaglio M, Zerbi A, Panzuto F, Pasquali C, Falconi M, Invernizzi P, On Behalf Of ItaNet Italian Association For Neuroendocrine Tumours Study Group. Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence? J Clin Med 2022;11:2658. [PMID: 35566783 DOI: 10.3390/jcm11092658] [Reference Citation Analysis]
108 Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780 [DOI: 10.3748/wjg.v28.i17.1768] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767 [DOI: 10.3748/wjg.v28.i17.1751] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chiappetta M, Lococo F, Sperduti I, Cusumano G, Terminella A, Fournel L, Guerrera F, Filosso P, Tabacco D, Nicosia S, Alifano M, Gallina F, Facciolo F, Margaritora S. Lymphadenectomy for lung carcinoids: Which factors may predict nodal upstaging? A multi centric, retrospective study. J Surg Oncol 2022. [PMID: 35522364 DOI: 10.1002/jso.26912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Li AY, Visser BC, Dua MM. Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement. Cancers 2022;14:2312. [DOI: 10.3390/cancers14092312] [Reference Citation Analysis]
112 Ichimaru C, Ishii T, Katanuma A. G1-Neuroendocrine tumor of gallbladder with unique dendritic morphology. J Hepatobiliary Pancreat Sci 2022. [PMID: 35510353 DOI: 10.1002/jhbp.1153] [Reference Citation Analysis]
113 Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol 2022. [PMID: 35507413 DOI: 10.1097/COC.0000000000000903] [Reference Citation Analysis]
114 Ye H, Yuan Y, Chen P, Zheng Q. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection. Surg Endosc 2022. [PMID: 35507062 DOI: 10.1007/s00464-022-09190-1] [Reference Citation Analysis]
115 Ma ST, Wang DY, Liu YB, Tan HJ, Ge YY, Chi Y, Zhang BL. Prognostic factors of primary neuroendocrine breast cancer: A population-based study. Cancer Med 2022. [PMID: 35499193 DOI: 10.1002/cam4.4557] [Reference Citation Analysis]
116 Wang Q, Zhang J, Xu L, Li X, Lu Y, Chen S, Jin Q. Primary hepatic neuroendocrine carcinoma with colon adenoma: A case report with literature review. International Journal of Surgery Case Reports 2022. [DOI: 10.1016/j.ijscr.2022.107176] [Reference Citation Analysis]
117 Inoue M, Tsukamoto S, Moritani K, Sekine H, Saito Y, Kanemitsu Y. A metastatic G2 neuroendocrine tumor smaller than 5 mm: A case report. International Journal of Surgery Case Reports 2022;94:107037. [DOI: 10.1016/j.ijscr.2022.107037] [Reference Citation Analysis]
118 Concors SJ, Maxwell JE. Neuroendocrine hepatic metastatic disease: the surgeon's perspective. Abdom Radiol (NY) 2022. [PMID: 35476146 DOI: 10.1007/s00261-022-03515-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Koizumi T, Otsuki K, Tanaka Y, Kanda S. Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 - 2015. BMC Endocr Disord 2022;22:105. [PMID: 35443668 DOI: 10.1186/s12902-022-01016-4] [Reference Citation Analysis]
120 Wang X, Qiu JJ, Tan CL, Chen YH, Tan QQ, Ren SJ, Yang F, Yao WQ, Cao D, Ke NW, Liu XB. Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Front Oncol 2022;12:843376. [PMID: 35433485 DOI: 10.3389/fonc.2022.843376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol 2022:S0046-8177(22)00099-5. [PMID: 35447141 DOI: 10.1016/j.humpath.2022.04.009] [Reference Citation Analysis]
122 Matsui T, Nagai H, Amanuma M, Kobayashi K, Ogino Y, Mukozu T, Wakui N, Okano N, Kikuchi Y, Matsuda T, Igarashi Y. Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literature. Clin J Gastroenterol. [DOI: 10.1007/s12328-022-01631-7] [Reference Citation Analysis]
123 Hernandez‐barco YG, Chung DC. Neuroendocrine tumors of the pancreas. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch80] [Reference Citation Analysis]
124 Komoto I, Kokudo N, Aoki T, Morizane C, Ito T, Hashimoto T, Kimura W, Inoue N, Hasegawa K, Kondo S, Ueno H, Igarashi H, Oono T, Makuuchi M, Takamoto T, Hirai I, Takeshita A, Imamura M. Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Jpn J Clin Oncol 2022:hyac048. [PMID: 35411926 DOI: 10.1093/jjco/hyac048] [Reference Citation Analysis]
125 Nakano S, Minaga K, Tani Y, Tonomura K, Hanawa Y, Morimura H, Terashita T, Matsumoto H, Iwagami H, Nakatani Y, Akamatsu T, Uenoyama Y, Maeda C, Ono K, Watanabe T, Yamashita Y. Primary Hepatic Neuroendocrine Carcinoma with Thrombocytopenia due to Diffuse Bone Marrow and Splenic Infiltration: An Autopsy Case. Intern Med 2022. [PMID: 35400708 DOI: 10.2169/internalmedicine.9465-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Appelstrand A, Bergstedt F, Elf AK, Fagman H, Hedenström P. Endoscopic ultrasound-guided side-fenestrated needle biopsy sampling is sensitive for pancreatic neuroendocrine tumors but inadequate for tumor grading: a prospective study. Sci Rep 2022;12:5971. [PMID: 35396490 DOI: 10.1038/s41598-022-09923-1] [Reference Citation Analysis]
127 Abdel-Rahman O, Ghosh S, Fazio N. Sex-based differences in the outcomes of patients with lung carcinoids. J Comp Eff Res 2022. [PMID: 35388711 DOI: 10.2217/cer-2021-0205] [Reference Citation Analysis]
128 Abdel-Rahman O, Pham TM, Pokhrel A, Ruether D, Sawyer MB. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study. Am J Clin Oncol 2022. [PMID: 35383575 DOI: 10.1097/COC.0000000000000906] [Reference Citation Analysis]
129 Hickman K, Sadler T, Zhang T, Boninsegna E, Majcher V, Godfrey E. Pancreatic cystic lesions and the role of contrast enhanced endoscopic ultrasound. Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.02.017] [Reference Citation Analysis]
130 Li D, Imbesi GJ, Yen L, Kim H, Sun CL, Crook CJ, Ballena R, Zhang YH, Allen R, Sedrak M, Singh G. Feasibility and Satisfaction of Using NET VITALS Self-assessment Tool Among Patients With Neuroendocrine Tumors. Pancreas 2022;51:319-24. [PMID: 35775639 DOI: 10.1097/MPA.0000000000002034] [Reference Citation Analysis]
131 Crook C, Zhang YH, Li D. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs Aging 2022;39:257-69. [PMID: 35332446 DOI: 10.1007/s40266-022-00934-1] [Reference Citation Analysis]
132 Maldonado-garcía E, Álvarez-barragán A, Acevedo-aguirre C, Galicia-alemán B, Arellano-gutiérrez G. Tumor neuroendocrino de válvula ileocecal: reporte de un caso y revisión de la literatura. Revista de Gastroenterología de México 2022;87:261-263. [DOI: 10.1016/j.rgmx.2021.04.007] [Reference Citation Analysis]
133 Asa SL, Ezzat S. Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine Oncology 2022;2:R14-R23. [DOI: 10.1530/eo-22-0041] [Reference Citation Analysis]
134 Mou Y, Wang ZY, Tan CL, Chen YH, Liu XB, Ke NW. The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases. Front Oncol 2022;12:838103. [PMID: 35350567 DOI: 10.3389/fonc.2022.838103] [Reference Citation Analysis]
135 Yang H, Xiao X, Mei T, Zhou P. Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study. Aging Clin Exp Res 2022. [PMID: 35347580 DOI: 10.1007/s40520-022-02112-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Yan L, Xu Y, Pan J, Bai J, Long Q, He N, Hu P, Liu M, Ji H, Li X, Tang Q, Wang J. Prognostic Evaluation of Patients with Rectal Neuroendocrine Neoplasms and Hepatic Metastases: A SEER Database Analysis. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/2451282] [Reference Citation Analysis]
137 Montes Escobar K, Vicente Villardón JL, Alarcón Cano DF, Siteneski A. Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach. Investigación Clínica 2022;63:19-31. [DOI: 10.54817/ic.v63n1a02] [Reference Citation Analysis]
138 Gupta A, Lubner MG, Liu JB, Richards ES, Pickhardt PJ. Small bowel neuroendocrine neoplasm: what surgeons want to know. Abdom Radiol (NY) 2022. [PMID: 35312820 DOI: 10.1007/s00261-022-03485-6] [Reference Citation Analysis]
139 Oh D, Pyo J, Chung KH, Son BK. The Predicting Role of the Neutrophil-to-Lymphocyte Ratio for the Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumors. Diagnostics 2022;12:737. [DOI: 10.3390/diagnostics12030737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 La Salvia A, Persano I, Siciliani A, Verrico M, Bassi M, Modica R, Audisio A, Zanata I, Trabalza Marinucci B, Trevisi E, Puliani G, Rinzivillo M, Parlagreco E, Baldelli R, Feola T, Sesti F, Razzore P, Mazzilli R, Mancini M, Panzuto F, Volante M, Giannetta E, Romero C, Appetecchia M, Isidori A, Venuta F, Ambrosio MR, Zatelli MC, Ibrahim M, Colao A, Brizzi MP, García-Carbonero R, Faggiano A. Prognostic significance of laterality in lung neuroendocrine tumors. Endocrine 2022. [PMID: 35301675 DOI: 10.1007/s12020-022-03015-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
141 Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, MIsidori A, Faggiano A, Colao AM; NIKE Group. Sex differences in carcinoid syndrome: A gap to be closed. Rev Endocr Metab Disord 2022. [PMID: 35292889 DOI: 10.1007/s11154-022-09719-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
142 Molasy B, Zemła P, Kuśnierz K. Skin Metastases of Gastrointestinal Neuroendocrine Tumors – Literature Review. Pol Przegl Chir 2022;94:60-65. [DOI: 10.5604/01.3001.0015.7958] [Reference Citation Analysis]
143 Siebenhüner AR, Langheinrich M, Friemel J, Schäfer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor. Cancers (Basel) 2022;14:1478. [PMID: 35326628 DOI: 10.3390/cancers14061478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Zhou J, Zhao R, Pan Y, Ju H, Huang X, Jiang Y, Jin J, Zhang Y. The Diagnostic and Grading Accuracy of 68Ga-DOTATATE and 18F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms. Front Oncol 2022;12:796391. [PMID: 35273910 DOI: 10.3389/fonc.2022.796391] [Reference Citation Analysis]
145 Sasaki N, Shinji S, Shichi Y, Ishiwata T, Arai T, Yamada T, Takahashi G, Ohta R, Sonoda H, Matsuda A, Iwai T, Takeda K, Yonaga K, Ueda K, Kuriyama S, Miyasaka T, Yoshida H. TGF-β1 increases cellular invasion of colorectal neuroendocrine carcinoma cell line through partial epithelial-mesenchymal transition. Biochem Biophys Rep 2022;30:101239. [PMID: 35252596 DOI: 10.1016/j.bbrep.2022.101239] [Reference Citation Analysis]
146 Rizen EN, Phan AT. Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep 2022. [PMID: 35254612 DOI: 10.1007/s11912-022-01217-z] [Reference Citation Analysis]
147 Hsiao TH, Wu CC, Tseng HH, Chen JH. Synchronous but separate neuroendocrine tumor and high-grade dysplasia/adenoma of the gall bladder: A case report. World J Clin Cases 2022;10:2322-9. [PMID: 35321155 DOI: 10.12998/wjcc.v10.i7.2322] [Reference Citation Analysis]
148 Mejia A, Vivian E, Nwogu C, Shah J, Longoria R, Vo A, Shahin I, Verma J, Bageac A. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting. Medicine (Baltimore) 2022;101:e28970. [PMID: 35244064 DOI: 10.1097/MD.0000000000028970] [Reference Citation Analysis]
149 Ishida H, Lam AK. Pancreatic Neuroendocrine Neoplasms: Updates on Genomic Changes in Inherited Tumour Syndromes and Sporadic Tumours Based on WHO Classification. Crit Rev Oncol Hematol 2022;:103648. [PMID: 35248713 DOI: 10.1016/j.critrevonc.2022.103648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
150 Ilhan H, Schnitzer M, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Onkologie up2date 2022;04:93-106. [DOI: 10.1055/a-1712-0674] [Reference Citation Analysis]
151 Tustumi F, Marques SSB, Barros EF, Henriques AC, Waisberg J, Dias AR. THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY. Arq Gastroenterol 2022;59:53-7. [DOI: 10.1590/s0004-2803.202200001-10] [Reference Citation Analysis]
152 Li APZ, Sathyanarayan S, Diaz-cano S, Arshad S, Drakou EE, Vincent RP, Grossman AB, Aylwin SJB, Dimitriadis GK. Multiple electrolyte disturbances as the presenting feature of multiple endocrine neoplasia type 1 (MEN-1). Endocrinology, Diabetes & Metabolism Case Reports 2022;2022. [DOI: 10.1530/edm-21-0207] [Reference Citation Analysis]
153 Zhang D, Lu L, Zhu H, Xiao Y, Han X, Du S, Xue H, Liu Q, Zhu Z, Hu M, Zhai X, Xing X, Lu Z, Reimondo G. Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature. International Journal of Endocrinology 2022;2022:1-10. [DOI: 10.1155/2022/6283706] [Reference Citation Analysis]
154 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
155 Begum N, Hunold H, Gerdes B, Keck T, Waldmann A. Anxiety, Depression and Quality of Life in Patients with Neuroendocrine Neoplasia After Surgery. World J Surg 2022. [PMID: 35194674 DOI: 10.1007/s00268-022-06479-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Masui T, Ito T, Komoto I, Kojima S, Kasai Y, Tanabe M, Hara K, Hirano S, Okusaka T, Ichikawa Y, Kinugasa Y, Kokudo N, Kudo A, Sakurai A, Sugihara K, Date H, Haruma K, Hijioka S, Hirata K, Yamano H, Sakamine M, Kikuchi T, Fukushima M, Imamura M, Uemoto S. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol 2022. [PMID: 35178624 DOI: 10.1007/s10147-022-02130-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Han IW, Park J, Park EY, Yoon SJ, Jin G, Hwang DW, Jiang K, Kwon W, Xu X, Heo JS, Fu DL, Lee WJ, Bai X, Yoon YS, Yang YM, Ahn KS, Yuan C, Lee HK, Sun B, Park EK, Lee SE, Kang S, Lou W, Park SJ. Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries. Cancers (Basel) 2022;14:1038. [PMID: 35205787 DOI: 10.3390/cancers14041038] [Reference Citation Analysis]
158 Laudicella R, Comelli A, Liberini V, Vento A, Stefano A, Spataro A, Crocè L, Baldari S, Bambaci M, Deandreis D, Arico’ D, Ippolito M, Gaeta M, Alongi P, Minutoli F, Burger IA, Baldari S. [68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The “Theragnomics” Concept. Cancers 2022;14:984. [DOI: 10.3390/cancers14040984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
159 Shannon AB, Straker RJ, Fraker DL, Miura JT, Karakousis GC. Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors. Journal of the American College of Surgeons 2022;234:900-9. [DOI: 10.1097/xcs.0000000000000144] [Reference Citation Analysis]
160 Bober B, Saracyn M, Zaręba K, Lubas A, Mazurkiewicz P, Wilińska E, Kamiński G. Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study. J Clin Med 2022;11:919. [PMID: 35207193 DOI: 10.3390/jcm11040919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Sharma S, Kapoor VK. Gastrointestinal Neuroendocrine Neoplasms. Indian Journal of Endocrine Surgery and Research 2022;16:51-58. [DOI: 10.5005/jp-journals-10088-11177] [Reference Citation Analysis]
162 Peng W, Cao L, Chen L, Lin G, Zhu B, Hu X, Lin Y, Zhang S, Jiang M, Wang J, Li J, Li C, Shao L, Du H, Hou T, Chen Z, Xiang J, Pu X, Li J, Xu F, Loong H, Wu L. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). The Oncologist 2022. [DOI: 10.1093/oncolo/oyab044] [Reference Citation Analysis]
163 Fujii M, Okamoto Y, Fujioka S, Yoshioka M, Shiode J. Neuroendocrine tumor of the ampulla of Vater showing chronological endoscopic changes. Clin J Gastroenterol 2022. [PMID: 35113343 DOI: 10.1007/s12328-021-01553-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Şentürk M, Acar B, Yildirim MA, Çakir M, Küçükkartallar T, Vatansev C. Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: 10 Years of Experience From a Single Center. Pancreas 2022;51:159-63. [DOI: 10.1097/mpa.0000000000001981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Bangla VG, Wolin EM, Kim MK, Divino CM. Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study. Pancreas 2022;51:171-6. [DOI: 10.1097/mpa.0000000000001982] [Reference Citation Analysis]
166 Zhao J, Wang H. Differential diagnostic value of 18F-FDG PET/CT in pulmonary carcinoids versus hamartomas. Acad Radiol 2022;29 Suppl 2:S41-6. [PMID: 33183953 DOI: 10.1016/j.acra.2020.10.022] [Reference Citation Analysis]
167 Reichart J, Lacoeuille F, Roquin G, Vervueren L, Morel O, Mention P. A case of heterotopic pancreas mimicking an intestinal neuroendocrine tumor in 18F-DOPA PET-CT and a review of the literature. Médecine Nucléaire 2022;46:10-13. [DOI: 10.1016/j.mednuc.2021.12.003] [Reference Citation Analysis]
168 Soldath P, Binderup T, Carstensen F, Clausen MM, Kjaer A, Federspiel B, Knigge U, Langer SW, Petersen RH. Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101728] [Reference Citation Analysis]
169 Müller C, Kreissl MC, Klose S, Krause A, Keitel V, Venerito M. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. Medicine (Baltimore) 2022;101:e28610. [PMID: 35089197 DOI: 10.1097/MD.0000000000028610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Chen G, Xu Q, Qian S, Wang Z, Wang S. Survival Analysis in Gastrointestinal Neuroendocrine Carcinoma With Bone Metastasis at Diagnosis. Front Surg 2022;9:820725. [DOI: 10.3389/fsurg.2022.820725] [Reference Citation Analysis]
171 Matli VVK, Wellman G, Jaganmohan S, Koticha K. Ampullary and Pancreatic Neuroendocrine Tumors: A Series of Cases and Review of the Literature. Cureus 2022. [DOI: 10.7759/cureus.21657] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Cope J, Srirajaskanthan R. Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation? Curr Oncol Rep 2022. [PMID: 35084662 DOI: 10.1007/s11912-021-01172-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
173 Shaib WL, Zakka K, Penley M, Jiang R, Akce M, Wu C, Maithel SK, Sarmiento JM, Kooby D, Behera M, Alese OB, El-Rayes BF. Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2021;50:1382-91. [PMID: 35041337 DOI: 10.1097/MPA.0000000000001936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Alexandraki KI, Zatelli MC, Grossman AB. "The past is a different country, they do things differently there": using the SEER data-base to assess prognosis in neuroendocrine tumours. Endocrine 2022. [PMID: 35037238 DOI: 10.1007/s12020-021-02959-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Salom F, Prat F. Current role of endoscopic ultrasound in the diagnosis and management of pancreatic cancer. World J Gastrointest Endosc 2022; 14(1): 35-48 [DOI: 10.4253/wjge.v14.i1.35] [Reference Citation Analysis]
176 Boeriu A, Dobru D, Fofiu C, Brusnic O, Onişor D, Mocan S. Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review. Medicine (Baltimore) 2022;101:e28550. [PMID: 35029217 DOI: 10.1097/MD.0000000000028550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Zheng X, Wu M, Er L, Deng H, Wang G, Jin L, Li S. Risk factors for lymph node metastasis and prognosis in colorectal neuroendocrine tumours. Int J Colorectal Dis 2022. [PMID: 34997303 DOI: 10.1007/s00384-021-04082-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Felux K, Mccarty B, Turner D, Gray T, Patel V. Poorly Differentiated Large Cell Neuroendocrine Carcinoma of the Colon: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.20949] [Reference Citation Analysis]
179 Ağalar C, Simsek GO. Management of the Patients with Carcinoma of Unknown Primary and the Role of Biomarkers. Biomarkers in Carcinoma of Unknown Primary 2022. [DOI: 10.1007/978-3-030-84432-5_14] [Reference Citation Analysis]
180 Melhorn P, Kretschmer-chott E, Wolff L, Haug A, Mazal P, Raderer M, Kiesewetter B. Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Ther Adv Med Oncol 2022;14:175883592211383. [DOI: 10.1177/17588359221138389] [Reference Citation Analysis]
181 Osama M, Rao S, Bhardwaj P, Mediratta G, Bhalla S, Badwal S. Neuroendocrine carcinoma of ovary: Hitherto rare entity in primary ovarian tumors. Indian J Pathol Microbiol 2022;0:0. [DOI: 10.4103/ijpm.ijpm_954_21] [Reference Citation Analysis]
182 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_17-4] [Reference Citation Analysis]
183 徐 新. Clinical Pathology, Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms. ACM 2022;12:4192-4200. [DOI: 10.12677/acm.2022.125608] [Reference Citation Analysis]
184 Kabasakal L, Demirci E, Selçuk NA. Radionuclide Therapy in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_9] [Reference Citation Analysis]
185 Bou Zerdan M, Hamouche R, Bouferraa Y, Chouairy C, Gholam D. Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report. SAGE Open Medical Case Reports 2022;10:2050313X2211069. [DOI: 10.1177/2050313x221106987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Shimaoka T, Hama N, Takiuchi D, Fukuda N, Harada S, Ota H. A Case of Recurrent Pancreatic Head Neuroendocrine Carcinoma Presented with Ectopic Acth Syndrome. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2022;83:762-767. [DOI: 10.3919/jjsa.83.762] [Reference Citation Analysis]
187 Bartsch D, Wiese D. Neuroendokrine Neoplasien. Allgemein- und Viszeralchirurgie II 2022. [DOI: 10.1016/b978-3-437-24812-2.00004-4] [Reference Citation Analysis]
188 Katiyar V, Das S, University of Louisville, Department of Medicine, Division of Medical Oncology and Hematology, Louisville, KY, USA, Vanderbilt University Medical Center, Department of Medicine, Division of Medical Oncology, Nashville, TN, USA. Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. Oncology & Haematology 2022;18:66. [DOI: 10.17925/ohr.2022.18.1.66] [Reference Citation Analysis]
189 Bartsch DK, Maurer E, Holzer K. Neuroendokrine Neoplasien des Jejunums und Ileums (SI-NEN). Springer Reference Medizin 2022. [DOI: 10.1007/978-3-662-61724-3_46-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Takeuchi S, Hirata K. Pet imaging in thymomas. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00208-8] [Reference Citation Analysis]
191 Hayes AR, Furtado O'Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, Toumpanakis C. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact. Clin Nucl Med 2022;47:26-35. [PMID: 34874347 DOI: 10.1097/RLU.0000000000003937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
192 Alavi K, Boutros M. Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, and Lymphoma. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Rosiek V, Wójcik-giertuga M, Kos-kudła B. Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms”. Cancer Treatment and Research Communications 2022;31:100533. [DOI: 10.1016/j.ctarc.2022.100533] [Reference Citation Analysis]
194 La Rosa S. Functioning Neuroendocrine Neoplasm. Endocrine Pathology 2022. [DOI: 10.1007/978-3-030-62345-6_5306] [Reference Citation Analysis]
195 German J, Burke LMB, Rowell JV. Clinical, Laboratory, and Radiological Diagnosis of Pancreatic Islet Cell Tumors. Diagnosis and Management of Endocrine Disorders in Interventional Radiology 2022. [DOI: 10.1007/978-3-030-87189-5_5] [Reference Citation Analysis]
196 Zhu J, Fu C, Zhang Y, Zhou X, Xiao W, Li Y. Observation Versus Resection for Small, Localized, and Nonfunctional Pancreatic Neuroendocrine Tumors: A Propensity Score Matching Study. Pancreas 2022;51:56-62. [PMID: 35195596 DOI: 10.1097/MPA.0000000000001959] [Reference Citation Analysis]
197 La Rosa S. Functioning Neuroendocrine Neoplasm. Encyclopedia of Pathology 2022. [DOI: 10.1007/978-3-319-28845-1_5306-1] [Reference Citation Analysis]
198 Wonn SM, Pommier RF. Carcinoid Syndrome and Carcinoid Crisis. Endocrine Emergencies 2022. [DOI: 10.1016/b978-0-323-76097-3.00017-x] [Reference Citation Analysis]
199 Wang Y, Chen J, Song C, Shi S, Li Z, Feng ST, Luo Y. Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. Eur J Radiol 2021;147:110119. [PMID: 34979297 DOI: 10.1016/j.ejrad.2021.110119] [Reference Citation Analysis]
200 Korol P, Ivakh M. Modern hybrid imaging of neuroendocrine tumors (clinical lecture). УРОЖ 2021;29:108-118. [DOI: 10.46879/ukroj.4.2021.108-118] [Reference Citation Analysis]
201 Sharma N, Sharma D. An Overview of Pancreatic Neuroendocrine Tumors. Challenges in Pancreatic Cancer 2021. [DOI: 10.5772/intechopen.96259] [Reference Citation Analysis]
202 Sun X, Wu Y, Shen J, Han C, Kang K, Liu Z, Zhang F. A Population-Based Systematic Clinical Analysis With a Single-Center Case Series of Patients With Pulmonary Large Cell Neuroendocrine Carcinoma. Front Endocrinol (Lausanne) 2021;12:759915. [PMID: 34925232 DOI: 10.3389/fendo.2021.759915] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Cazzato RL, Hubelé F, De Marini P, Ouvrard E, Salvadori J, Addeo P, Garnon J, Kurtz JE, Greget M, Mertz L, Goichot B, Gangi A, Imperiale A. Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. Cancers (Basel) 2021;13:6368. [PMID: 34944988 DOI: 10.3390/cancers13246368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
205 Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res 2021;13:9085-93. [PMID: 34916851 DOI: 10.2147/CMAR.S343572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Caplin ME. Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? EJC Suppl 2021;16:1-4. [PMID: 34912477 DOI: 10.1016/j.ejcsup.2021.06.001] [Reference Citation Analysis]
207 Weerasuriya S, Palmer K, Gregory S, Whitelaw BC, Gonzalez E, Srirajaskanthan R. Mesenteric Variceal Haemorrhage and Ectopic Cushing's Syndrome as Presenting Features of a Pancreatic Neuroendocrine Tumour Recurrence. Case Rep Gastroenterol 2021;15:919-26. [PMID: 34899150 DOI: 10.1159/000518021] [Reference Citation Analysis]
208 Hoft SG, Noto CN, DiPaolo RJ. Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity. Front Cell Dev Biol 2021;9:752346. [PMID: 34900999 DOI: 10.3389/fcell.2021.752346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
209 Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci 2021. [PMID: 34907652 DOI: 10.1002/jhbp.1101] [Reference Citation Analysis]
210 Halperin R, Ahron-Hananel G, Badarna M, Greidinger D, Uri I, Percik R, Tirosh A. Plasma Hemoglobin and Red Blood Cell Mass Levels as Dynamic Prognostic Markers for Progression and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021;53:810-7. [PMID: 34891211 DOI: 10.1055/a-1672-4653] [Reference Citation Analysis]
211 Yu H, Li M, Cao D, Wang Y, Zeng N, Cheng Y, Huang Z, Song B. Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5. Eur J Radiol 2021;147:110100. [PMID: 34972060 DOI: 10.1016/j.ejrad.2021.110100] [Reference Citation Analysis]
212 Nießen A, Schimmack S, Sandini M, Fliegner D, Hinz U, Lewosinska M, Hackert T, Büchler MW, Strobel O. C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms. Sci Rep 2021;11:23768. [PMID: 34887479 DOI: 10.1038/s41598-021-03187-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
213 Maurer E, Heinzel-Gutenbrunner M, Rinke A, Rütz J, Holzer K, Figiel J, Luster M, Bartsch DK. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. J Neuroendocrinol 2021;:e13076. [PMID: 34964186 DOI: 10.1111/jne.13076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
214 Tsai HJ, Hsiao CF, Chang JS, Chen LT, Chao YJ, Yen CJ, Shan YS. The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors - A Single-Center Experience. Front Oncol 2021;11:741096. [PMID: 34868938 DOI: 10.3389/fonc.2021.741096] [Reference Citation Analysis]
215 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
216 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Der Nuklearmediziner 2021;44:313-325. [DOI: 10.1055/a-1652-4899] [Reference Citation Analysis]
217 Aufort S, Aubé C, de Baere T, Kobeiter H, Luciani A, Ronot M, Sapoval M, Soyer P, Tasu J, Wagner M, Seror O. Recommandation opérationnelle en radiologie interventionnelle : chimioembolisation hépatique. Journal d'imagerie diagnostique et interventionnelle 2021;4:357-361. [DOI: 10.1016/j.jidi.2021.05.002] [Reference Citation Analysis]
218 Rayes N, Denecke T. Gastroenteropankreatische neuroendokrine Tumoren. Gastroenterologe 2021;16:469-479. [DOI: 10.1007/s11377-021-00576-6] [Reference Citation Analysis]
219 Buck AK, Lapa C, Weich A, Higuchi T, Hasenauer N, Hänscheid H, Werner RA. Peptidradiorezeptor-Therapie (PRRT). Der Nuklearmediziner 2021;44:334-343. [DOI: 10.1055/a-1556-8323] [Reference Citation Analysis]
220 Duan S, Rico K, Merchant JL. Gastrin: From Physiology to Gastrointestinal Malignancies. Function 2022;3:zqab062. [DOI: 10.1093/function/zqab062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
221 Walter MA, Nesti C, Spanjol M, Kollár A, Bütikofer L, Gloy VL, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Kaderli RM. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database Syst Rev 2021;11:CD013700. [PMID: 34822169 DOI: 10.1002/14651858.CD013700.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
222 Deacon MJ, Harvey H, Shah C, Khan A. A Rare Case of a Large Primary Renal Neuroendocrine Tumour: A Case Report and Brief Review of Literature. Cureus 2021;13:e19743. [PMID: 34812336 DOI: 10.7759/cureus.19743] [Reference Citation Analysis]
223 Michael M, Thursfield V, Te Marvelde L, Kong G, Hicks RJ. Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region. Asia Pac J Clin Oncol 2021. [PMID: 34821050 DOI: 10.1111/ajco.13671] [Reference Citation Analysis]
224 Cheng X, Li J, Xu T, Li K, Li J. Predicting Survival of Patients With Rectal Neuroendocrine Tumors Using Machine Learning: A SEER-Based Population Study. Front Surg 2021;8:745220. [PMID: 34805260 DOI: 10.3389/fsurg.2021.745220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:1752-63. [PMID: 34793718 DOI: 10.1016/S1470-2045(21)00572-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 35.0] [Reference Citation Analysis]
226 Maldonado-García EL, Álvarez-Barragán AF, Acevedo-Aguirre CE, Galicia-Alemán B, Arellano-Gutiérrez G. Neuroendocrine tumor of the ileocecal valve: A case report and review of the literature. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00123-7. [PMID: 34794925 DOI: 10.1016/j.rgmxen.2021.11.008] [Reference Citation Analysis]
227 Li Y, Pan F, Sun G, Wang ZK, Meng K, Peng LH, Lu ZS, Dou Y, Yan B, Liu QS. Risk Factors and Clinical Outcomes of 54 Cases of Rectal Neuroendocrine Tumors with Incomplete Resection: A Retrospective Single-Center Study. Ther Clin Risk Manag 2021;17:1153-61. [PMID: 34764651 DOI: 10.2147/TCRM.S332838] [Reference Citation Analysis]
228 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
229 Krug S, Kegel T, Gress TM, Rinke A, Apostolidis L, Jann H, König A, Hörsch D, Schrader J, Ettrich TJ, Richter M, Steighardt J, Michl P. Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial. BMC Cancer 2021;21:1206. [PMID: 34772353 DOI: 10.1186/s12885-021-08900-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Rico K, Duan S, Pandey RL, Chen Y, Chakrabarti JT, Starr J, Zavros Y, Else T, Katona BW, Metz DC, Merchant JL. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. BMJ Open Gastroenterol 2021;8:e000765. [PMID: 34750164 DOI: 10.1136/bmjgast-2021-000765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
231 Nasir N, Akhlaq S, Shehzad T, Fatimi S. Endobronchial carcinoid presenting as Focal bronchiectasis in a young woman with systemic lupus erythematosus. Clin Case Rep 2021;9:e04840. [PMID: 34745611 DOI: 10.1002/ccr3.4840] [Reference Citation Analysis]
232 Li Q, Chen Q, Chen J, Wang Z, Wang P, Zhao H, Zhao J. Prognostic nomogram for predicting long-term survival in bronchopulmonary carcinoid tumor patients receiving resection. Ann Transl Med 2021;9:1402. [PMID: 34733954 DOI: 10.21037/atm-21-1929] [Reference Citation Analysis]
233 Rayes N, Denecke T. [Gastroenteropancreatic neuroendocrine tumors]. Radiologe 2021. [PMID: 34727206 DOI: 10.1007/s00117-021-00929-w] [Reference Citation Analysis]
234 Bateni SB, Coburn NG, Law CHL, Singh S, Myrehaug S, Assal A, Hallet J. Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors. JAMA Oncol 2021;7:1718-20. [PMID: 34591069 DOI: 10.1001/jamaoncol.2021.4531] [Reference Citation Analysis]
235 Alvarez-Villegas D, Giménez-Milà M, Sbraga F, Camprubí I, Gil A, Valchanov K, Shayan H, Castillo J, Weiner MM. Dealing With the Right Side: Carcinoid Heart Disease. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00950-2. [PMID: 34863651 DOI: 10.1053/j.jvca.2021.10.030] [Reference Citation Analysis]
236 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
237 Broadbent R, Wheatley R, Stajer S, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E, McNamara MG. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;101:102299. [PMID: 34662810 DOI: 10.1016/j.ctrv.2021.102299] [Reference Citation Analysis]
238 Zhang Z, Zhong D, Feng T, Yao Y, Huang X. Mixed Adenoneuroendocrine Carcinoma of the Gallbladder. J Gastrointest Surg 2021. [PMID: 34668162 DOI: 10.1007/s11605-021-05139-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
240 Gao H, Wang W, Yu X, Liu L. Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike? Crit Rev Oncol Hematol 2021;167:103493. [PMID: 34653597 DOI: 10.1016/j.critrevonc.2021.103493] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Carpizo DR, Harris CR. Genetic Drivers of Ileal Neuroendocrine Tumors. Cancers (Basel) 2021;13:5070. [PMID: 34680217 DOI: 10.3390/cancers13205070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
242 Moncer F, Adhoum N, Catak D, Monser L. Electrochemical sensor based on MIP for highly sensitive detection of 5-hydroxyindole-3-acetic acid carcinoid cancer biomarker in human biological fluids. Anal Chim Acta 2021;1181:338925. [PMID: 34556226 DOI: 10.1016/j.aca.2021.338925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
243 Sato H, Saito T, Horii H, Kajiura M, Kikuchi N, Takada N, Taguchi K, Yoshida M, Hasegawa M, Taguchi H, Yoshida Y, Ando K, Fujiya M, Omori Y, Hank T, Liss AS, Gala MK, Makita Y, Ono Y, Mizukami Y, Okumura T. Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Front Genet 2021;12:608324. [PMID: 34616420 DOI: 10.3389/fgene.2021.608324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Carvão J, Dinis-Ribeiro M, Pimentel-Nunes P, Libânio D. Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists. GE Port J Gastroenterol 2021;28:336-48. [PMID: 34604465 DOI: 10.1159/000512089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
245 Li C, Zhang P, Sun X, Tong X, Chen X, Li C, Yang W, Liu W, Wang Z, Tao K. Risk Factors and Predictive Score Model for Early Recurrence After Curative Surgery in Patients With Poorly Differentiated Gastrointestinal Neuroendocrine Neoplasms. Front Surg 2021;8:703138. [PMID: 34604293 DOI: 10.3389/fsurg.2021.703138] [Reference Citation Analysis]
246 Wehrend J, Silosky M, Xing F, Chin BB. Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network. EJNMMI Res 2021;11:98. [PMID: 34601660 DOI: 10.1186/s13550-021-00839-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
247 Thapi S, Baeg K, Kim MK, Gallagher EJ. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus. Pancreas 2021;50:1293-7. [PMID: 34860814 DOI: 10.1097/MPA.0000000000001911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Murase Y, Kudo A, Akahoshi K, Maekawa A, Ishikawa Y, Ueda H, Ogawa K, Ono H, Tanaka S, Tanabe M. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms. Ann Gastroenterol Surg 2021;5:692-700. [PMID: 34585054 DOI: 10.1002/ags3.12458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Shimizu Y, Kanda S, Fukushima T, Kobayashi T, Kondo R, Koizumi T. Increased carbohydrate antigen 19-9 expression in a thymic neuroendocrine tumor. Thorac Cancer 2021;12:2949-52. [PMID: 34581018 DOI: 10.1111/1759-7714.14153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Alì G, Di Stefano I, Poma AM, Ricci S, Proietti A, Davini F, Lucchi M, Melfi F, Fontanini G. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Front Oncol 2021;11:729765. [PMID: 34568063 DOI: 10.3389/fonc.2021.729765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
251 Shim JR, Kim JR, Park Y, Seo HI. Small-cell neuroendocrine carcinoma arising from an extra-hepatic bile duct: a case report. Gastroenterol Rep (Oxf) 2021;9:380-2. [PMID: 34567573 DOI: 10.1093/gastro/goaa051] [Reference Citation Analysis]
252 Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, Isidori A, Colao A; NIKE. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord 2020;21:599-612. [PMID: 32152781 DOI: 10.1007/s11154-020-09547-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
253 Strojan P, Šifrer R, Ferlito A, Grašič-Kuhar C, Lanišnik B, Plavc G, Zidar N. Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study. Cancers (Basel) 2021;13:4813. [PMID: 34638312 DOI: 10.3390/cancers13194813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
255 Marini F, Giusti F, Brandi ML. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. Expert Rev Endocrinol Metab 2021;:1-13. [PMID: 34554891 DOI: 10.1080/17446651.2021.1982382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
257 Jacob A, Gabriel G, Ramirez RA, Wang Y, Anthony L, Chauhan A. How I Treat Neuroendocrine Tumors. Indian J Med Paediatr Oncol 2021;42:470-8. [DOI: 10.1055/s-0041-1732833] [Reference Citation Analysis]
258 Zhou Z, Wang Z, Zhang B, Wu Y, Li G, Wang Z. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:727327. [PMID: 34539577 DOI: 10.3389/fendo.2021.727327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Do MY, Jang SI, Kang HP, Kim EJ, Lee KJ, Park GE, Lee SJ, Lee DK, Woo SM, Cho JH. Comparison of the Clinical Features and Outcomes of Gallbladder Neuroendocrine Carcinoma with Those of Adenocarcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:4713. [PMID: 34572940 DOI: 10.3390/cancers13184713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Escobar KM, Vicente-villardon JL, de la Hoz-m J, Useche-castro LM, Alarcón Cano DF, Siteneski A. Frequency of Neuroendocrine Tumor Studies: Using Latent Dirichlet Allocation and HJ-Biplot Statistical Methods. Mathematics 2021;9:2281. [DOI: 10.3390/math9182281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
261 Gonulal B, Bilgic Y, Akbulut S, Karabulut E, Samdanci ET. Management and Survival Analysis of Gastrointestinal Neuroendocrine Tumors by Different Tumor Characteristics: Tertiary Center Experience. J Gastrointest Cancer 2021. [PMID: 34524616 DOI: 10.1007/s12029-021-00709-8] [Reference Citation Analysis]
262 Uccelli L, Boschi A, Cittanti C, Martini P, Panareo S, Tonini E, Nieri A, Urso L, Caracciolo M, Lodi L, Carnevale A, Giganti M, Bartolomei M. 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans. Pharmaceutics 2021;13:1463. [PMID: 34575538 DOI: 10.3390/pharmaceutics13091463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
263 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
264 Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 2021. [PMID: 34480724 DOI: 10.1007/s12020-021-02859-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 2021;4:e2124750. [PMID: 34554237 DOI: 10.1001/jamanetworkopen.2021.24750] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 23.0] [Reference Citation Analysis]
266 Khanna A, Cianci N, Abbas Shah H, Goel A, Jebril A, Chauhan J, Pipe M, Shetty S, Weston C, Venkataraman H, Smith S, Vickrage S, Kemp‐blake J, Shah T. Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours. GastroHep 2021;3:291-297. [DOI: 10.1002/ygh2.491] [Reference Citation Analysis]
267 Chen Q, Ning Z, Liu Z, Zhou Y, He Q, Tian Y, Hao H, Lin W, Jiang L, Zhao G, Li P, Zheng C, Huang C; Study Group for Gastric Neuroendocrine Tumors. Textbook Outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis. Chin J Cancer Res 2021;33:433-46. [PMID: 34584369 DOI: 10.21147/j.issn.1000-9604.2021.04.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
268 Abdel-Rahman O. Assessment of the AJCC staging system of pheochromocytomas/paragangliomas. Endocrine 2021. [PMID: 34449032 DOI: 10.1007/s12020-021-02854-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, Pradella S, Recchia L, Brunese L, Miele V. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging. Radiol Med 2021;126:1497-507. [PMID: 34427861 DOI: 10.1007/s11547-021-01408-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
270 Abdelmalak R, Lythgoe MP, Evans J, Flynn M, Waters J, Webb A, Pinato DJ, Sharma R. Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. Cancers (Basel) 2021;13:4232. [PMID: 34439386 DOI: 10.3390/cancers13164232] [Reference Citation Analysis]
271 Atkinson C, Ganeshan B, Endozo R, Wan S, Aldridge MD, Groves AM, Bomanji JB, Gaze MN. Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With 177Lu-DOTATATE. Front Oncol 2021;11:686235. [PMID: 34408979 DOI: 10.3389/fonc.2021.686235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
272 Sharma R, Lythgoe MP, Slaich B, Patel N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers (Basel) 2021;13:4181. [PMID: 34439335 DOI: 10.3390/cancers13164181] [Reference Citation Analysis]
273 Calabrese F, Fortarezza F, Pezzuto F, Lunardi F, Comacchio G, Sbaraglia M, Pasello G, Marulli G, Dei Tos AP, Rea F. The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience. Cancers (Basel) 2021;13:4056. [PMID: 34439210 DOI: 10.3390/cancers13164056] [Reference Citation Analysis]
274 Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:185-208. [PMID: 32151355 DOI: 10.1016/j.soc.2019.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
275 Xu R, Zhou B, Hu P, Xue B, Gu D, Li X, Tang Q. Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms. World J Surg Oncol 2021;19:233. [PMID: 34364382 DOI: 10.1186/s12957-021-02338-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
276 Folkestad O, Wasmuth HH, Mjønes P, Fougner R, Hauso Ø, Fossmark R. Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort. Cancers (Basel) 2021;13:3985. [PMID: 34439140 DOI: 10.3390/cancers13163985] [Reference Citation Analysis]
277 Webster AP, Thirlwell C. The evolving molecular landscape of intestinal and pulmonary neuroendocrine tumours. Current Opinion in Endocrine and Metabolic Research 2021;19:30-34. [DOI: 10.1016/j.coemr.2021.05.004] [Reference Citation Analysis]
278 Ronot M, Vullierme M. Morphological imaging of gastrointestinal and lung neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;19:1-7. [DOI: 10.1016/j.coemr.2021.05.001] [Reference Citation Analysis]
279 Domingo-sabugo C, Willis-owen SA, Mandal A, Nastase A, Dwyer S, Brambilla C, Gálvez JH, Zhuang Q, Popat S, Eveleigh R, Munter M, Lim E, Nicholson AG, Lathrop M, Cookson WO, Moffatt MF. Distinct pancreatic and neuronal Lung Carcinoid molecular subtypes revealed by integrative omic analysis.. [DOI: 10.1101/2021.07.27.21260865] [Reference Citation Analysis]
280 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
281 Mullangi S, Lekkala MR, Raghu Subramanian C, Nemer O, Singh J, Kichloo A, Moftakhar B. Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan. J Investig Med High Impact Case Rep 2021;9:23247096211035232. [PMID: 34311624 DOI: 10.1177/23247096211035232] [Reference Citation Analysis]
282 Zhou S, Jiang S, Chen W, Yin H, Dong L, Zhao H, Han S, He X. Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram. Front Oncol 2021;11:654439. [PMID: 34350109 DOI: 10.3389/fonc.2021.654439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Zhang JZ, Li S, Zhu WH, Zhang DF. Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases. World J Clin Cases 2021; 9(19): 5064-5072 [PMID: 34307557 DOI: 10.12998/wjcc.v9.i19.5064] [Reference Citation Analysis]
284 Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle PJ, Verslype C, Borbath I, Demetter P, Van Damme N, Van Eycken L, Vandamme T, Hoorens A, Geboes K. Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015. Acta Gastroenterol Belg 2021;84:458-66. [PMID: 34599571 DOI: 10.51821/84.3.011] [Reference Citation Analysis]
285 Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, Langer SW, Kjaer A, Arola J, Schalin-Jäntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2021;60:931-41. [PMID: 33999752 DOI: 10.1080/0284186X.2021.1921262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
286 Li J, Lin Y, Wang Y, Lin H, Lin F, Zhuang Q, Lin X, Wu J. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. ESMO Open 2020;5:e000632. [PMID: 32253246 DOI: 10.1136/esmoopen-2019-000632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
287 Korotaeva A, Mansorunov D, Apanovich N, Kuzevanova A, Karpukhin A. MiRNA Expression in Neuroendocrine Neoplasms of Frequent Localizations. Noncoding RNA 2021;7:38. [PMID: 34202122 DOI: 10.3390/ncrna7030038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
288 Telo S, Filice A, Versari A, Lamberti G, Campana D, Calabrò D, Fanti S, Ambrosini V. Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clin Transl Imaging 2021;9:423-38. [DOI: 10.1007/s40336-021-00443-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
289 Kim J, Kim J, Oh EH, Ham NS, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK, Hong SM, Yang DH. Anchoring the snare tip is a feasible endoscopic mucosal resection method for small rectal neuroendocrine tumors. Sci Rep 2021;11:12918. [PMID: 34155319 DOI: 10.1038/s41598-021-92462-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Wang F, Xu X, Ye Z, Qin Y, Yu X, Ji S. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:691557. [PMID: 34220718 DOI: 10.3389/fendo.2021.691557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
291 Gao LP, Kong GX, Wang X, Ma HM, Ding FF, Li TD. Pancreatic neuroendocrine carcinoma in a pregnant woman: A case report and review of the literature . World J Clin Cases 2021; 9(17): 4327-4335 [PMID: 34141797 DOI: 10.12998/wjcc.v9.i17.4327] [Reference Citation Analysis]
292 Melita G, Pallio S, Tortora A, Crinò SF, Macrì A, Dionigi G. Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms. J Clin Med 2021;10:2638. [PMID: 34203922 DOI: 10.3390/jcm10122638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
293 Hiltunen N, Väyrynen JP, Böhm J, Helminen O. CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. Diseases 2021;9:42. [PMID: 34208144 DOI: 10.3390/diseases9020042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
294 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
295 Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One 2021;16:e0252574. [PMID: 34077464 DOI: 10.1371/journal.pone.0252574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Rodrigues M, Svirydenka H, Virgolini I. Theragnostics in Neuroendocrine Tumors. PET Clin 2021;16:365-73. [PMID: 34053580 DOI: 10.1016/j.cpet.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Yu Q, Tan X, Li D, Shi B, Wu F, Xu D, Xue W, Wang Z. Automated radiosynthesis of [18F]AlF-NOTA-octreotide and PET/CT imaging in NENs. J Radioanal Nucl Chem 2021;328:825-833. [DOI: 10.1007/s10967-021-07746-4] [Reference Citation Analysis]
298 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Taha M, Samavati L. Sarcoidosis and neuroendocrine tumours: case report and literature review. Respirol Case Rep 2021;9:e00784. [PMID: 34094569 DOI: 10.1002/rcr2.784] [Reference Citation Analysis]
300 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
301 Mahoney RC, Awad K, Maldini G. Metastatic neuroendocrine tumor with metastases to the right liver in a patient with absent left portal vein. Journal of Surgical Case Reports 2021;2021:rjab207. [DOI: 10.1093/jscr/rjab207] [Reference Citation Analysis]
302 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
303 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Wang P, Chen J, Jiang Y, Jia C, Pang J, Wang S, Chang X. Neuroendocrine Neoplasms of the Gallbladder: A Clinicopathological Analysis of 13 Patients and a Review of the Literature. Gastroenterol Res Pract 2021;2021:5592525. [PMID: 34122537 DOI: 10.1155/2021/5592525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Chu H, Jin L, Shi Y, Dou C, Wei F, Zhang C, Zhang J, Huang D. Laparoscopic Surgery for Gallbladder Neuroendocrine Carcinoma: a Case Series and Literature Review. Indian J Surg 2021;83:789-94. [DOI: 10.1007/s12262-021-02923-x] [Reference Citation Analysis]
306 Nassereddine H, Chicaud M, Rebah K, Théou-Anton N, Sautet A, Dermer J, Couvelard A. Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms. Endocr Pathol 2021. [PMID: 34019237 DOI: 10.1007/s12022-021-09681-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
307 Asa SL, Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S, Grossman AB, Ezzat S; Attendees of the 15th Meeting of the International Pituitary Pathology Club, Istanbul October 2019. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 2021;34:1634-50. [PMID: 34017065 DOI: 10.1038/s41379-021-00820-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
308 Zhang Z, Zhao X, Li Z, Wu Y, Liu Y, Li Z, Li G. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer 2021;21:567. [PMID: 34006241 DOI: 10.1186/s12885-021-08337-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
309 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
310 Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021;14:476. [PMID: 34067837 DOI: 10.3390/ph14050476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
311 Cao S, Li J, Yang K, Zhang J, Xu J, Feng C, Li H. Development and validation of a novel prognostic model for long-term overall survival in liposarcoma patients: a population-based study. J Int Med Res 2020;48:300060520975882. [PMID: 33296604 DOI: 10.1177/0300060520975882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
312 Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 2021;11:10252. [PMID: 33986468 DOI: 10.1038/s41598-021-89866-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
313 Krokker L, Patócs A, Butz H. Essential Role of the 14q32 Encoded miRNAs in Endocrine Tumors. Genes (Basel) 2021;12:698. [PMID: 34066712 DOI: 10.3390/genes12050698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
314 Heidsma CM, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Poultsides GA, Cho CS, Lopez-Aguiar AG, Kanji Z, Fisher AV, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CHJ, Nieveen van Dijkum EJM, Maithel SK, Pawlik TM. Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers (Basel) 2021;13:2242. [PMID: 34067017 DOI: 10.3390/cancers13092242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
316 Tong Z, Wang L, Shi W, Zeng Y, Zhang H, Liu L, Zheng Y, Chen C, Xia W, Fang W, Zhao P. Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms. Front Med (Lausanne) 2021;8:620988. [PMID: 34026777 DOI: 10.3389/fmed.2021.620988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
317 Rayes N, Denecke T. Gastroenteropankreatische neuroendokrine Tumoren. Onkologe 2021;27:511-520. [DOI: 10.1007/s00761-021-00911-0] [Reference Citation Analysis]
318 Lee W, Kim MJ, Choi Y, Kim H. PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis. Transl Cancer Res 2021;10:2210-8. [PMID: 35116539 DOI: 10.21037/tcr-20-3482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics (Basel) 2021;11:804. [PMID: 33925256 DOI: 10.3390/diagnostics11050804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
320 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
321 Venugopal A, Gillick-Walker J, Michalczyk A, Khasraw M, Ackland ML. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report. BMC Gastroenterol 2021;21:194. [PMID: 33906633 DOI: 10.1186/s12876-021-01705-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
323 Dou D, Li XK, Xia QS, Chen YY, Li YL, Wang C, Qi ZR, Tan HY. Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric neuroendocrine neoplasms. BMC Gastroenterol 2021;21:188. [PMID: 33892648 DOI: 10.1186/s12876-021-01769-7] [Reference Citation Analysis]
324 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
325 Tashima T, Ryozawa S, Tanisaka Y, Fujita A, Miyaguchi K, Ogawa T, Mizuide M, Mashimo Y, Kawasaki T, Yasuda M. Endoscopic resection using an over-the-scope clip for duodenal neuroendocrine tumors. Endosc Int Open 2021;9:E659-66. [PMID: 33937505 DOI: 10.1055/a-1374-6141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
326 Wikberg E, van Essen M, Rydén T, Svensson J, Gjertsson P, Bernhardt P. Evaluation of the Spatial Resolution In monte Carlo-Based Spect/Ct Reconstruction Of 111In-Octreotide Images. Radiat Prot Dosimetry 2021:ncab055. [PMID: 33885133 DOI: 10.1093/rpd/ncab055] [Reference Citation Analysis]
327 Pettersson OJ, Fröss-Baron K, Crona J, Sundin A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr Connect 2021;10:422-31. [PMID: 33875614 DOI: 10.1530/EC-21-0027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Pal DB, Tiwari AK, Srivastava N, Hashem A, Abd Allah EF. Thermal studies of biomass obtained from the seeds of Syzygium cumini and Cassia fistula L. and peel of Cassia fistula L. fruit. Biomass Conv Bioref . [DOI: 10.1007/s13399-021-01492-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
329 Hayes AR, Smith K, Liu M, Jenkinson S, Grossman AB, Youle M, Burns F, Thirlwell C, Caplin ME. Treating neuroendocrine neoplasms in the setting of HIV infection. TRD 2021;5:143-159. [DOI: 10.3233/trd-200046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021;7:27. [PMID: 33859205 DOI: 10.1038/s41572-021-00261-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 34.0] [Reference Citation Analysis]
331 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
332 Stankard M, Soule E, Matteo J. Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor. Gastrointest Tumors 2021;8:138-43. [PMID: 34307313 DOI: 10.1159/000514113] [Reference Citation Analysis]
333 Zhang J, Zeng M. Cardiac metastasis of neuroendocrine tumor of the thymus diagnosed by cardiac magnetic resonance T1 mapping: a case report. J Int Med Res 2020;48:300060520931678. [PMID: 32558603 DOI: 10.1177/0300060520931678] [Reference Citation Analysis]
334 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep 2021;11:7881. [PMID: 33846396 DOI: 10.1038/s41598-021-86839-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
335 Mowrey K, Northrup H, Rougeau P, Hashmi SS, Krueger DA, Ebrahimi-Fakhari D, Towbin AJ, Trout AT, Capal JK, Franz DN, Rodriguez-Buritica D. Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Front Neurol 2021;12:627672. [PMID: 33897589 DOI: 10.3389/fneur.2021.627672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
336 Chen L, Navalkissoor S, Quigley AM, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin ME, Hayes AR. 177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. Eur J Nucl Med Mol Imaging 2021;48:3582-94. [PMID: 33835221 DOI: 10.1007/s00259-021-05332-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
337 Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 2021;13:1753. [PMID: 33916960 DOI: 10.3390/cancers13081753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
338 Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Transl Gastroenterol Hepatol 2021;6:27. [PMID: 33824931 DOI: 10.21037/tgh-19-282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
339 La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? Cancers (Basel) 2021;13:1701. [PMID: 33916707 DOI: 10.3390/cancers13071701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
340 Yoon JY, Kumta NA, Kim MK. The Role of Endoscopy in Small Bowel Neuroendocrine Tumors. Clin Endosc 2021. [PMID: 33794563 DOI: 10.5946/ce.2020.296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
341 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol 2021;12:845-55. [PMID: 34012671 DOI: 10.21037/jgo-20-292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Süveg K, Putora PM, Joerger M, Iseli T, Fischer GF, Ammann K, Glatzer M. Radiotherapy for thymic epithelial tumours: a review. Transl Lung Cancer Res 2021;10:2088-100. [PMID: 34012817 DOI: 10.21037/tlcr-20-458] [Reference Citation Analysis]
343 Miura T, Ohtsuka H, Aoki T, Aoki S, Hata T, Takadate T, Maeda S, Ariake K, Kawaguchi K, Masuda K, Ishida M, Mizuma M, Nakagawa K, Morikawa T, Fujishima F, Kamei T, Sasano H, Unno M. Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. BMC Surg 2021;21:176. [PMID: 33789657 DOI: 10.1186/s12893-021-01178-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
344 Wang Q, Yu C. Expression profiling of small intestinal neuroendocrine tumors identified pathways and gene networks linked to tumorigenesis and metastasis. Biosci Rep 2020;40:BSR20193860. [PMID: 32496505 DOI: 10.1042/BSR20193860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
345 Lea D, Gudlaugsson EG, Skaland I, Lillesand M, Søreide K, Søreide JA. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index. Appl Immunohistochem Mol Morphol 2021;29:499-505. [PMID: 33758143 DOI: 10.1097/PAI.0000000000000934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
346 Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, Faggiano A, Colao A, Savastano S. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:649496. [PMID: 33815296 DOI: 10.3389/fendo.2021.649496] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
347 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
348 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 44.0] [Reference Citation Analysis]
349 Li YW, He YP, Liu FQ, Peng JJ, Cai SJ, Xu Y, Wang MH. Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor. Front Oncol 2021;11:646536. [PMID: 33777809 DOI: 10.3389/fonc.2021.646536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Jung SW. Endoscopic Treatment of Gastric and Duodenal Neuroendocrine Tumors: Present and Future. Korean J Helicobacter Up Gastrointest Res 2021;21:29-34. [DOI: 10.7704/kjhugr.2020.0055] [Reference Citation Analysis]
351 de Bitter TJJ, Kroeze LI, de Reuver PR, van Vliet S, Vink-Börger E, von Rhein D, Jansen EAM, Nagtegaal ID, Ligtenberg MJL, van der Post RS. Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization. JCO Precis Oncol 2021;5:PO. [PMID: 34036234 DOI: 10.1200/PO.20.00487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Kaur J, Mogulla S, Malik A, Garg S. Unusual Presentation of a Sphenoidal Sinus Neuroendocrine Tumor: A Case Report and Review of Literature. Cureus 2021;13:e13689. [PMID: 33833913 DOI: 10.7759/cureus.13689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Eeckhout K, Van Cotthem K, Guerti K. Evaluation of three commercially available ELISA kits for the determination of chromogranin A. J Immunoassay Immunochem 2021;42:95-105. [PMID: 33043835 DOI: 10.1080/15321819.2020.1830105] [Reference Citation Analysis]
354 Minutoli F, Cardile D, Laudicella R, Vento A, Pagano B, Baldari S. Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience. Nucl Med Mol Imaging 2021;55:38-45. [PMID: 33643488 DOI: 10.1007/s13139-020-00679-y] [Reference Citation Analysis]
355 Yi C, Dai J, Song N, Wu C, Zhang L, Zhu Y, Jiang G, Zhang H, Zhang P. Improvement of pathological staging system for neuroendocrine tumors of the lung. Ann Transl Med 2021;9:447. [PMID: 33850844 DOI: 10.21037/atm-20-5910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
356 Ban DM, Koscheski P. A Primary Hepatic Neuroendocrine Carcinoma. AR 2021. [DOI: 10.37549/ar2713] [Reference Citation Analysis]
357 Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review. Abdom Radiol (NY) 2021;46:919-35. [PMID: 32960304 DOI: 10.1007/s00261-020-02773-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
358 Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Eads JR, Katona BW. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2021;4:e212274. [PMID: 33755166 DOI: 10.1001/jamanetworkopen.2021.2274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
359 Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open 2021;4:e210945. [PMID: 33734413 DOI: 10.1001/jamanetworkopen.2021.0945] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
360 Volante M, Mete O, Pelosi G, Roden AC, Speel EJM, Uccella S. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:154-68. [PMID: 33641055 DOI: 10.1007/s12022-021-09668-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
361 Rao X, Chen W, Li J, Peng G, Wu G, Zhou R, Ding Q. Primary thymic atypical carcinoid with rare multiple bone metastasis: A case report and literature review. Mol Clin Oncol 2021;14:78. [PMID: 33758659 DOI: 10.3892/mco.2021.2240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Klimov S, Xue Y, Gertych A, Graham RP, Jiang Y, Bhattarai S, Pandol SJ, Rakha EA, Reid MD, Aneja R. Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. Front Oncol 2020;10:593211. [PMID: 33718106 DOI: 10.3389/fonc.2020.593211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
363 Jiang S, Wu H, Fu R, Mai J, Yao J, Hua X, Chen H, Liu J, Lu M, Li N. The Outcome of Primary Hepatic Carcinoid Tumor: A Retrospective Study Based on Propensity Score Matched Survival Analysis. Front Oncol 2021;11:609397. [PMID: 33718162 DOI: 10.3389/fonc.2021.609397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:334. [PMID: 33670457 DOI: 10.3390/diagnostics11020334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
365 Roohi S, Rizvi SK, Naqvi SAR. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models. Dose Response 2021;19:1559325821990147. [PMID: 33628154 DOI: 10.1177/1559325821990147] [Reference Citation Analysis]
366 Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? J Endocr Soc 2021;5:bvaa205. [PMID: 33604494 DOI: 10.1210/jendso/bvaa205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
367 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PHG, Kessler J, Li D, Singh G, Chang S. Natural History of Renal Neuroendocrine Neoplasms: A NET by Any Other Name? Front Endocrinol (Lausanne) 2020;11:624251. [PMID: 33613455 DOI: 10.3389/fendo.2020.624251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
368 Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat 2021;186:403-15. [PMID: 33528758 DOI: 10.1007/s10549-021-06099-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
369 Ando K, Fujiya M, Yoshida M, Kobayashi Y, Sugiyama Y, Murakami Y, Iwama T, Sato H, Sasaki T, Kunogi T, Takahashi K, Ueno N, Kashima S, Moriichi K, Tanabe H, Okumura T. Cardiac Metastasis Caused Fatal Ventricular Arrhythmia in a Patient with a Rectal Neuroendocrine Tumor. Intern Med 2021;60:373-8. [PMID: 33518610 DOI: 10.2169/internalmedicine.5208-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
370 Liu M, Sun X, Zhang Z, Xu X, Yu X, Zhuo Q, Ji S. The clinical characteristics and survival associations of pancreatic neuroendocrine tumors: does age matter? Gland Surg 2021;10:574-83. [PMID: 33708541 DOI: 10.21037/gs-20-634] [Reference Citation Analysis]
371 Milione M, Parente P, Grillo F, Zamboni G, Mastracci L, Capella C, Fassan M, Vanoli A. Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. Pathologica 2021;113:12-8. [PMID: 33686306 DOI: 10.32074/1591-951X-228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
372 Li WX, Miao F, Xu XQ, Zhang J, Wu ZY, Chen KM, Yan FH, Lin XZ. Pancreatic Neuroendocrine Neoplasms: CT Spectral Imaging in Grading. Acad Radiol 2021;28:208-16. [PMID: 32111466 DOI: 10.1016/j.acra.2020.01.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
373 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
374 Xiang QY, Xu J, Liu L. A rare case of thymic carcinoid presenting with gastrointestinal symptoms and pericardium effusion. BMC Cardiovasc Disord 2021;21:54. [PMID: 33509095 DOI: 10.1186/s12872-021-01871-4] [Reference Citation Analysis]
375 Chen JX, Lin Y, Meng YL, Zhao AX, Huang XJ, Liang R, Li YQ, Liu ZH. Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram. Biomed Res Int 2021;2021:9126351. [PMID: 33575356 DOI: 10.1155/2021/9126351] [Reference Citation Analysis]
376 Magi L, Rinzivillo M, Panzuto F. Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. Endocrines 2021;2:28-36. [DOI: 10.3390/endocrines2010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
378 Sethi A, Islam M, Moses R, Finley G. Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma. Cureus 2021;13:e12748. [PMID: 33643724 DOI: 10.7759/cureus.12748] [Reference Citation Analysis]
379 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
380 Arif AA, Kim PTW, Melck A, Churg A, Schwartz Z, Stuart HC. Pancreatic Gastrinoma, Gastrointestinal Stromal Tumor (GIST), Pheochromocytoma, and Hürthle Cell Neoplasm in a Patient with Neurofibromatosis Type 1: A Case Report and Literature Review. Am J Case Rep 2021;22:e927761. [PMID: 33452231 DOI: 10.12659/AJCR.927761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
381 Chu KK, Wong KH, Chok KS. Expanding Indications for Liver Transplant: Tumor and Patient Factors. Gut Liver 2021;15:19-30. [PMID: 32102130 DOI: 10.5009/gnl19265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
383 Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival? Orphanet J Rare Dis 2021;16:30. [PMID: 33446229 DOI: 10.1186/s13023-021-01677-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 Duan H, Baratto L, Laudicella R, Stracuzzi F, Baldari S, Iagaru A. Molecular imaging of pancreatic neoplasms. Clin Transl Imaging 2021;9:141-51. [DOI: 10.1007/s40336-020-00408-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Hashmi AA, Ali J, Yaqeen SR, Ahmed O, Asghar IA, Irfan M, Asif MG, Edhi MM, Hashmi S. Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors. Cureus 2021;13:e12640. [PMID: 33585126 DOI: 10.7759/cureus.12640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
386 Deng S, Fan Z, Xia H, Gong Y, Qian Y, Huang Q, Cheng H, Jin K, Xiao Z, Luo G, Yu X, Liu C. Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. Cancer Manag Res 2021;13:107-15. [PMID: 33447083 DOI: 10.2147/CMAR.S275173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
387 Landerholm K. Time trends in incidence and survival of small intestinal cancer in Sweden. BJS Open 2021;5:zraa044. [PMID: 33609370 DOI: 10.1093/bjsopen/zraa044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Sakamaki Y, Tanaka R, Ishida D, Tsuji H, Mike A, Yasuoka H. Pigmented spindle cell variant of a thymic atypical carcinoid in an octogenarian. Surg Case Rep 2021;7:12. [PMID: 33409736 DOI: 10.1186/s40792-020-01094-3] [Reference Citation Analysis]
389 Dromain C, Loaiza-Bonilla A, Mirakhur B, Beveridge TJR, Fojo AT. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist 2021;26:e632-8. [PMID: 33393112 DOI: 10.1002/onco.13669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
390 Tidjane A, Boudjenan N, Bengueddach A, Kadri A, Ikhlef N, Benmaarouf N, Tabeti B. Pure large cell neuroendocrine carcinoma of the gallbladder, is surgical relentlessness beneficial? A case report and literature review. Int Cancer Conf J 2021;:1-7. [PMID: 33425643 DOI: 10.1007/s13691-020-00461-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
391 Grimaldi F, Vescini F, Kara E. Treatment of NET-Related Symptoms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_7] [Reference Citation Analysis]
392 Stier MW, Chapman CG, Shamah S, Donboli K, Yassan L, Waxman I, Siddiqui UD. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open 2021;9:E4-8. [PMID: 33403229 DOI: 10.1055/a-1300-1017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
393 Mahvi DA, Clancy TE. Gastroduodenal NETs. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_7] [Reference Citation Analysis]
394 Limouris GS. Intravenous Radiopeptide Infusions with High Activity of 111In-Octreotide. Liver Intra-arterial PRRT with 111In-Octreotide 2021. [DOI: 10.1007/978-3-030-70773-6_6] [Reference Citation Analysis]
395 Kaderli RM, Simon D. Non-functional Pancreatic Neuroendocrine Tumors. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_28] [Reference Citation Analysis]
396 Pitchumoni CS, Chaubal A, Desai G. Gastric Tumors (Other than Adenocarcinoma). Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_117] [Reference Citation Analysis]
397 Keutgen XM, Vaghaiwalla TM. Surgical Evaluation of Appendiceal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_12] [Reference Citation Analysis]
398 Andreasi V, Partelli S, Muffatti F, Falconi M. New Surgical Strategies. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_8] [Reference Citation Analysis]
399 Di Matteo FM, Stigliano S. Endoscopic Ultrasound-Guided Therapies for Solid Pancreatic Tumors. Endoscopic Ultrasound Management of Pancreatic Lesions 2021. [DOI: 10.1007/978-3-030-71937-1_14] [Reference Citation Analysis]
400 Hadatsuki H, Noda S, Yokoi K, Mashita Y, Sugimoto H, Mochizuki Y. A Case of Left Supraclavicular Neuroendocrine Tumor of Unknown Primary Origin Overlapped with Right Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2021;82:2123-2129. [DOI: 10.3919/jjsa.82.2123] [Reference Citation Analysis]
401 Kishimoto Y, Ogura T, Takahashi A, Amikura K, Kawashima Y, Sakamoto H, Kanda H, Ishikawa A. A Case of Pancreatic Neuroendocrine Neoplasm with Para-aortic Lymph Node Metasatases without Reccurence for 7 Years after Resection. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2021;82:174-179. [DOI: 10.3919/jjsa.82.174] [Reference Citation Analysis]
402 Yamamoto H, Ogawa K, Tamura K, Sakamoto K, Takai A, Takada Y, Kitazawa R. A Case of Primary Hepatic Neuroendocrine Tumor with Suspected Bile Duct Invasion and Difficulty in Preoperative Diagnosis. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2021;82:151-158. [DOI: 10.3919/jjsa.82.151] [Reference Citation Analysis]
403 Pitchumoni CS, Chaubal A, Desai G. Gastric Tumors (Other than Adenocarcinoma). Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-319-90761-1_117-1] [Reference Citation Analysis]
404 Rinke A, Denzer UW. Kolorektale NEN (ohne Fernmetastasen). Springer Reference Medizin 2021. [DOI: 10.1007/978-3-662-61724-3_48-1] [Reference Citation Analysis]
405 Orsi F, Bonomo G. Locoregional Therapies of NEN. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_10] [Reference Citation Analysis]
406 董 玉. Clinical Characteristics and Treatment of Hepatic Neurorndorine Neoplasms. ACM 2021;11:5391-5397. [DOI: 10.12677/acm.2021.1111797] [Reference Citation Analysis]
407 Xu W, Yan H, Xu L, Li M, Gao W, Jiang K, Wu J, Miao Y. Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms. J Biomed Res 2020;35:179-88. [PMID: 33637654 DOI: 10.7555/JBR.34.20200039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Hodge C, Fahy BN. Palliative Interventions for Metastatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_19] [Reference Citation Analysis]
409 Gupta M, Prinzing G, Iyer R. Emerging Systemic Therapies for Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_20] [Reference Citation Analysis]
410 Romanet P, Goudet P, Barlier A. Multiple Endocrine Neoplasia Type 1. Endocrinology 2021. [DOI: 10.1007/978-3-319-89497-3_8] [Reference Citation Analysis]
411 Passlick B, Le U. Seltene maligne Lungentumoren. Thoraxchirurgie 2021. [DOI: 10.1007/978-3-662-59159-8_37-1] [Reference Citation Analysis]
412 Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol 2020;27:e537-46. [PMID: 33380868 DOI: 10.3747/co.27.6205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
413 Ravizza D, Fiori G. Gastric Neuroendocrine Tumors. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_13] [Reference Citation Analysis]
414 Das S, Soares H, Dasari A. Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_5] [Reference Citation Analysis]
415 Prinzi N, Rossi RE, Leuzzi G, Pusceddu S. NETs of the Lung. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_12] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Betella N, Smiroldo V, Baldelli R, Lania A. Treatment of NETs from Rare Origin. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_16] [Reference Citation Analysis]
417 Filosso PL, Fontana EC, Roffinella M. Primary Neuroendocrine Tumors of the Lung. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_13] [Reference Citation Analysis]
418 Goldmann A, Clerici T. Small Intestine NETs. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_29] [Reference Citation Analysis]
419 Twickler MTB, Regieli J, Grobben R, Hart EA, Tesselaar ME, Meijer RCA, Chamuleau SAJ, Nathoe HM. Impact of Endocrine Disorders on the Heart. Endocrinology 2021. [DOI: 10.1007/978-3-319-68729-2_3] [Reference Citation Analysis]
420 Asa SL, Lloyd RV, Tischler AS. Neuroendocrine Neoplasms: Historical Background and Terminologies. The Spectrum of Neuroendocrine Neoplasia 2021. [DOI: 10.1007/978-3-030-54391-4_1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Volante M, Pelosi G. Thoracic (Lung/Thymus) Neuroendocrine Neoplasms. The Spectrum of Neuroendocrine Neoplasia 2021. [DOI: 10.1007/978-3-030-54391-4_9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
422 Stechman MJ, Bränström R. Neuroendocrine Tumors (Thymic and Gastroenteropancreatic): Anatomy, Endocrine Physiology, and Pathophysiology. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_24] [Reference Citation Analysis]
423 Asa SL, Klimstra DS. Pancreatic Neuroendocrine Neoplasms. The Spectrum of Neuroendocrine Neoplasia 2021. [DOI: 10.1007/978-3-030-54391-4_11] [Reference Citation Analysis]
424 Hasril M, Luthfy M, Riana A, Ittaqa AN, Pawiro SA, Hardiansyah D. Study the effect of the physiological parameters to the optimal administration of lysine/arginine during peptide receptor radionuclide therapy (PPRT) using a physiologically-based pharmacokinetic (PBPK) model. PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in Medicine and Biomedical Applications 2021. [DOI: 10.1063/5.0047911] [Reference Citation Analysis]
425 Huppert P, Kortes N, Kratochwil C, Radeleff B, Schmitz A, Stampfl U. Onkologische Embolisation. Angiofibel 2021. [DOI: 10.1007/978-3-662-56243-7_14] [Reference Citation Analysis]
426 Wang J, Doherty G. Neuroendocrine Tumors: Stomach. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_26] [Reference Citation Analysis]
427 Kyriazanos I, Limouris GS. Cytoreductive Surgery in Peritoneal Neuroendocrine Neoplasm Metastases: The Adjuvant Endoperitoneal PRRT with 111In-Octreotide Perspective. Liver Intra-arterial PRRT with 111In-Octreotide 2021. [DOI: 10.1007/978-3-030-70773-6_19] [Reference Citation Analysis]
428 Sherman SK, Howe JR. Jejunoileal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_10] [Reference Citation Analysis]
429 Fields AC, Lu PW, Melnitchouk N. Colon and Rectal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_11] [Reference Citation Analysis]
430 Trama A. Epidemiology of Neuroendocrine Neoplasms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Fathizadeh P, Wang HL, Dietz RL. Pathologic Basis and Classification of Biliary Epithelial Neoplasms. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_4] [Reference Citation Analysis]
432 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
433 Alawad M, Gupta R, Haseeb MA, Brunicardi FC. Clinicopathologic and Molecular Features of Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder. Gastroenterology Res 2020;13:269-78. [PMID: 33447306 DOI: 10.14740/gr1323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
434 Lorz C, Oteo M, Santos M. Neuroendocrine Lung Cancer Mouse Models: An Overview. Cancers (Basel) 2020;13:E14. [PMID: 33375066 DOI: 10.3390/cancers13010014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
435 Jakhetiya A, Garg PK, Pandey R, Ramanathan P, Kumar S, Nath D, Pandey D. Surgical management of bronchopulmonary carcinoids: A single center experience. South Asian J Cancer 2017;6:6-10. [PMID: 28413786 DOI: 10.4103/2278-330X.202568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
436 Lokesh KN, Anand A, Lakshmaiah KC, Babu KG, Lokanatha D, Jacob LA, Babu MCS, Rudresha AH, Rajeev LK, Saldanha SC, Giri GV, Panwar D, Koppaka D, Patidar R. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer 2018;7:207-9. [PMID: 30112343 DOI: 10.4103/sajc.sajc_176_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
437 Colao A, de Nigris F, Modica R, Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front Endocrinol (Lausanne) 2020;11:604341. [PMID: 33384663 DOI: 10.3389/fendo.2020.604341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
438 Widmeier E, Füllgraf H, Waller CF. Complete remission of Cdx-2 positive primary testicular carcinoid tumor: 10-years follow-up and literature review. BMC Urol 2020;20:197. [PMID: 33317491 DOI: 10.1186/s12894-020-00768-2] [Reference Citation Analysis]
439 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
440 Lehrman ED, Fidelman N. Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy. Semin Intervent Radiol 2020;37:499-507. [PMID: 33328706 DOI: 10.1055/s-0040-1720951] [Reference Citation Analysis]
441 Watzka FM, Meyer F, Staubitz JI, Fottner C, Schad A, Lang H, Musholt TJ. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies. World J Surg 2020;44:594-603. [PMID: 31605171 DOI: 10.1007/s00268-019-05220-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
442 Manzia T, Parente A, Angelico R, Gazia C, Tisone G. The Revolution in Indication for Liver Transplantation: Will Liver Metastatic Disease Overcome the End-Stage Liver Disease in the Next Future? Transplantology 2020;1:111-22. [DOI: 10.3390/transplantology1020011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
443 Xiao C, Song B, Yi P, Xie Y, Li B, Lian P, Ding S, Lu Y. Deaths of colon neuroendocrine tumors are associated with increasing metastatic lymph nodes and lymph node ratio. J Gastrointest Oncol 2020;11:1146-54. [PMID: 33456989 DOI: 10.21037/jgo-20-444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Gao S, Shi X, Ma H, Wang H, Li B, Song B, Guo S, Jin G. The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection. Journal of Pancreatology 2020;3:167-72. [DOI: 10.1097/jp9.0000000000000058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
445 Pepe G, Lania A. Terapia radiorecettoriale dei tumori neuroendocrini. L'Endocrinologo 2020;21:410-416. [DOI: 10.1007/s40619-020-00792-2] [Reference Citation Analysis]
446 Dherange P, Telles N, Modi K. Flow-driven right-to-left cardiac shunting in a patient with carcinoid heart disease and patent foramen ovale without elevated right atrial pressure: a case report and literature review. European Heart Journal - Case Reports 2020;4:1-5. [DOI: 10.1093/ehjcr/ytaa301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
447 Ebrahimi AJ, Marogil P, Von Mering G, Ahmed M. A clinical and echocardiographic case report of carcinoid-related valvular heart disease. European Heart Journal - Case Reports 2020;4:1-4. [DOI: 10.1093/ehjcr/ytaa363] [Reference Citation Analysis]
448 Plaza López PJ, Suarez Pinera M, Mestre Fusco A, Domenech Brasero B, Pifarré Muntané P, Rivera Codias E. Clinical impact of Ga68-DOTATOC PET/CT on neuroendocrine tumors. A preliminary experience. Endocrinología, Diabetes y Nutrición (English ed ) 2020;67:636-642. [DOI: 10.1016/j.endien.2019.12.008] [Reference Citation Analysis]
449 Özdirik B, Amthauer H, Schatka I, Goretzki PE, Mogl MT, Fehrenbach U, Tacke F, Jann H, Roderburg C. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Mol Clin Oncol 2021;14:20. [PMID: 33363730 DOI: 10.3892/mco.2020.2182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
450 Mori R, Yamashita SI, Midorikawa K, Abe S, Inada K, Yoneda S, Okabayashi K, Nabeshima K. CDX2 Expression and Prognostic Factors of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma. Clin Med Insights Oncol 2020;14:1179554920967319. [PMID: 33293882 DOI: 10.1177/1179554920967319] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
451 Liu S, Zhong Z, Xiao M, Song Y, Zhu Y, Hu B, Sun Z, Yi W, Peng C. Mixed adenoneuroendocrine carcinoma of the hepatic bile duct: a case report and review of the literature. BMC Gastroenterol 2020;20:399. [PMID: 33238879 DOI: 10.1186/s12876-020-01550-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
452 Chubakova GV, Polikarpova SB, Kozlov NA. Tumors of appendix: modern understanding about features of clinical course, diagnosis, treatment and prognosis (literature review). Medicinskij alfavit 2020. [DOI: 10.33667/2078-5631-2020-29-48-53] [Reference Citation Analysis]
453 Yamaguchi T, Takahashi K, Yamada K, Bando H, Baba H, Ito M, Funahashi K, Ueno H, Fujita S, Hasegawa S, Sakai Y, Sugihara K. A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. Ann Gastroenterol Surg 2021;5:215-20. [PMID: 33860141 DOI: 10.1002/ags3.12403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
454 Imperatore N, de Nucci G, Mandelli ED, de Leone A, Zito FP, Lombardi G, Manes G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature. Endosc Int Open 2020;8:E1759-64. [PMID: 33269308 DOI: 10.1055/a-1261-9605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
455 de Nucci G, Imperatore N, Mandelli ED, di Nuovo F, d'Urbano C, Manes G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series. Endosc Int Open 2020;8:E1754-8. [PMID: 33269307 DOI: 10.1055/a-1261-9359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
456 Masui T, Ito T, Komoto I, Uemoto S; JNETS Project Study Group. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer 2020;20:1104. [PMID: 33189127 DOI: 10.1186/s12885-020-07581-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
457 Olpin J, Fine GC, Shaaban A. Imaging of Gastrointestinal Neuroendocrine Tumors. Curr Radiol Rep 2020;8. [DOI: 10.1007/s40134-020-00371-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Kimura K, Tsuchiya J, Kitazume Y, Kishino M, Akahoshi K, Kudo A, Tanaka S, Tanabe M, Tateishi U. Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study. Diagnostics (Basel) 2020;10:E919. [PMID: 33182335 DOI: 10.3390/diagnostics10110919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
459 Peinado P, Arco CDD, Fernández-aceñero MJ. Neuroendocrine tumors in rare locations: Description of 27 cases. Medicina Clínica (English Edition) 2020;155:460-461. [DOI: 10.1016/j.medcle.2019.05.040] [Reference Citation Analysis]
460 Tomihara H, Hashimoto K, Wakasa T, Ishikawa H, Tsujimoto T, Gakuhara A, Fukuda S, Ohta K, Kitani K, Hida JI, Ohta Y, Yukawa M. Successful resection of a neuroendocrine tumor in the gallbladder: a case report. Surg Case Rep 2020;6:274. [PMID: 33108599 DOI: 10.1186/s40792-020-01055-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
461 Aburjania Z, Whitt JD, Jang S, Nadkarni DH, Chen H, Rose JB, Velu SE, Jaskula-Sztul R. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules 2020;25:E4940. [PMID: 33114525 DOI: 10.3390/molecules25214940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
462 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY) 2020. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
463 Ren S, Qian L, Daniels MJ, Duan S, Chen R, Wang Z. Evaluation of contrast-enhanced computed tomography for the differential diagnosis of hypovascular pancreatic neuroendocrine tumors from chronic mass-forming pancreatitis. Eur J Radiol 2020;133:109360. [PMID: 33126171 DOI: 10.1016/j.ejrad.2020.109360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
464 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
465 Alwan H, La Rosa S, Andreas Kopp P, Germann S, Maspoli-Conconi M, Sempoux C, Bulliard JL. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland. Cancer Med 2020;9:9454-61. [PMID: 33078908 DOI: 10.1002/cam4.3524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
466 Goksu SY, Ozer M, Beg MS, Sanford NN, Ahn C, Fangman BD, Goksu BB, Verma U, Sanjeevaiah A, Hsiehchen D, Jones AL, Kainthla R, Kazmi SM. Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2990. [PMID: 33076486 DOI: 10.3390/cancers12102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
467 Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB, Xie JW, Li P, Xu Y, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH. Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 2020;20:1002. [PMID: 33059606 DOI: 10.1186/s12885-020-07506-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
468 Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, Li TJ, Xu HX, Li H, Ye LY, Lin X, Wu CT, Long J, Yu XJ, Liu L. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer 2020;8:e001188. [PMID: 33055204 DOI: 10.1136/jitc-2020-001188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
469 Sampedro-Núñez M, Bouthelier A, Serrano-Somavilla A, Martínez-Hernández R, Adrados M, Martín-Pérez E, Muñoz de Nova JL, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Díaz JÁ, García-Centeno R, Aragones J, Marazuela M. LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2968. [PMID: 33066332 DOI: 10.3390/cancers12102968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
470 Jo H, Park Y, Kim J, Kwon H, Kim T, Lee J, Pyun JC, Lee M, Yun M. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells. PLoS One 2020;15:e0240107. [PMID: 33045023 DOI: 10.1371/journal.pone.0240107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
471 Bagrova SG, Emelyanova GS, Gorbunova VA, Kolomeytseva AA, Lyubimova NV, Markovich АA, Besova NS, Kovalenko ЕI, Artamonova EV. Derivatives of nitrosoureas in treatment of patients with neuroendocrine tumors. Clinical case of successful treatment of patient with disseminated highly differentiated neuroendocrine pancreatic tumor with severe carcinoid syndrome in fourth line of therapy. Medicinskij alfavit 2020. [DOI: 10.33667/2078-5631-2020-20-38-41] [Reference Citation Analysis]
472 Yang M, Zeng L, Hou SZ, Ke NW, Tian BL, Liu XB, Xiang B, Zhang Y. Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification. J Oncol 2020;2020:6572398. [PMID: 33014053 DOI: 10.1155/2020/6572398] [Reference Citation Analysis]
473 Zinchenko EI, Maslak OS, Pischik VG, Obornev AD, Kovalenko AI. Pleural Metastasis of Atypical Bronchial Carcinoid. Korean J Thorac Cardiovasc Surg 2020;53:317-20. [PMID: 32919450 DOI: 10.5090/kjtcs.19.098] [Reference Citation Analysis]
474 Souquet P, Girard N, Gérinière L, Arpin D. Tumeurs neuro-endocrines broncho-pulmonaires primitives : tumeurs carcinoïdes et carcinomes neuro-endocrines à grandes cellules. Revue des Maladies Respiratoires Actualités 2020;12:2S132-2S140. [DOI: 10.1016/s1877-1203(20)30094-x] [Reference Citation Analysis]
475 Pascual-corrales E, Araujo-castro M, Ortiz-flores A, Escobar-morreale H. Tumores neuroendocrinos. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:1019-1028. [DOI: 10.1016/j.med.2020.10.004] [Reference Citation Analysis]
476 Hendifar AE, Ramirez RA, Anthony LB, Liu E. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas 2019;48:1111-8. [PMID: 31609931 DOI: 10.1097/MPA.0000000000001391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
477 Kessoku T, Kobayashi N, Yoneda M, Kasai Y, Ozaki A, Okubo N, Iwaki M, Kobayashi T, Yoshihara T, Kurita Y, Honda Y, Tokuhisa M, Ishiki H, Hibiya T, Fujii S, Nakajima A, Ichikawa Y. Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. Front Oncol 2020;10:555963. [PMID: 33102220 DOI: 10.3389/fonc.2020.555963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
478 Chu H, Zhang C, Shi Y, Wu W, Hu Z, Zhang J, Huang D. Gallbladder neuroendocrine carcinoma: A single center experience. Medicine (Baltimore) 2020;99:e21912. [PMID: 32899024 DOI: 10.1097/MD.0000000000021912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
479 Yang M, Zeng L, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer 2020;20:906. [PMID: 32962649 DOI: 10.1186/s12885-020-07356-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
480 Xie J, Chen P, Xie H, Sun Y, Huang Z, Wei R, Miao Z, Wang Q, Zhang SD, Wong KH, Lin Y, Huang C, Kwok HF. Exploration of gastric neuroendocrine carcinoma (GNEC) specific signaling pathways involved in chemoresistance via transcriptome and in vitro analysis. Comput Struct Biotechnol J 2020;18:2610-20. [PMID: 33033581 DOI: 10.1016/j.csbj.2020.09.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
481 Souche R, Hobeika C, Hain E, Gaujoux S. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. 2020;9. [PMID: 32947997 DOI: 10.3390/jcm9092993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
482 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
483 Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg 2020;4:652-9. [PMID: 33319155 DOI: 10.1002/ags3.12396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
484 Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol 2020;15:108. [PMID: 32917216 DOI: 10.1186/s13000-020-01030-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
485 Tsang ES, Loree JM, Speers C, Kennecke HF. Sequence of therapy and survival in patients with advanced pancreatic neuroendocrine tumours. Curr Oncol 2020;27:215-9. [PMID: 32905342 DOI: 10.3747/co.27.5929] [Reference Citation Analysis]
486 Feng X, Wei G, Wang W, Zhang Y, Zeng Y, Chen M, Chen Y, Chen J, Zhou Z, Li Y. Nomogram for individually predicting overall survival in rectal neuroendocrine tumours. BMC Cancer 2020;20:865. [PMID: 32907602 DOI: 10.1186/s12885-020-07328-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
487 Kanzaki T, Takahashi Y, Higuchi T, Zhang X, Mogi N, Suto T, Tsushima Y. Evaluation of a Correction Method for 111In-Pentetreotide SPECT Imaging of Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med Technol 2020;48:326-30. [PMID: 32887762 DOI: 10.2967/jnmt.120.249680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
488 Goksu SY, Ozer M, Kazmi SMA, Sanford NN, Aguilera TA, Ahn C, Hsiehchen D, Sanjeevaiah A, Khosama L, Bleeker J, Atiq M, Beg MS. Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. Cancers (Basel) 2020;12:E2501. [PMID: 32899271 DOI: 10.3390/cancers12092501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
489 Parghane RV, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Talole S, Shrikhande SV, Basu S. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging 2021;48:913-23. [PMID: 32876706 DOI: 10.1007/s00259-020-05004-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
490 Kövesdi A, Kurucz PA, Nyírő G, Darvasi O, Patócs A, Butz H. Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2488. [PMID: 32887459 DOI: 10.3390/cancers12092488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
491 Giraldi L, Vecchioni A, Carioli G, Bilotta M, La Rosa S, Imperatori A, Volante M, Brizzi MP, Inzani F, Petrone G, Schinzari G, Bianchi A, Margaritora S, Alfieri S, La Vecchia C, Boccia S, Rindi G. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. Endocrine 2021;71:233-41. [PMID: 32869113 DOI: 10.1007/s12020-020-02464-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
492 Tanno L, Pea A, Nykänen T, Prasad P, Tuncer C, Marchegiani G, Robinson S. Role of Pre-operative Inflammatory Markers as Predictors of Lymph Node Positivity and Disease Recurrence in Well-Differentiated Pancreatic Neuroendocrine Tumours: Pancreas2000 Research and Educational Program (Course 9). Front Med (Lausanne) 2020;7:346. [PMID: 32850881 DOI: 10.3389/fmed.2020.00346] [Reference Citation Analysis]
493 Hasanov R, Samadov E, Bayramov N, Ünlü A, Petrone P. Surgical management of insulinomas at the Azerbaijan Medical University: a retrospective study of 21 cases over a 10-year period. Turk J Med Sci 2020;50:1262-9. [PMID: 32394681 DOI: 10.3906/sag-2001-150] [Reference Citation Analysis]
494 Costa RDD, Kemp R, Santos JSD, Costa DAPD, Ardengh JC, Ribas-Filho JM, Ribas CAPM. THE ROLE OF CONVENTIONAL ECHOENDOSCOPY (EUS) IN THERAPEUTIC DECISIONS IN PATIENTS WITH NEUROENDOCRINE GASTROINTESTINAL TUMORS. Arq Bras Cir Dig 2020;33:e1512. [PMID: 32844878 DOI: 10.1590/0102-672020190001e1512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
495 Cha JW, Yang M, Mo A. Large cell neuroendocrine carcinoma in the unusual location of the descending colon. Radiol Case Rep 2020;15:1841-4. [PMID: 32817774 DOI: 10.1016/j.radcr.2020.07.045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
497 Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Duh MS, Seth K, Lapuerta P, Metz DC. Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study. Cancer Manag Res 2020;12:6607-14. [PMID: 32801896 DOI: 10.2147/CMAR.S261257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
498 Bauckneht M, Albano D, Annunziata S, Santo G, Guglielmo P, Frantellizzi V, Branca A, Ferrari C, Vento A, Mirabile A, Nappi AG, Evangelista L, Alongi P, Laudicella R. Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2020;10:E598. [PMID: 32824388 DOI: 10.3390/diagnostics10080598] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
499 Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 2020; 12(8): 791-807 [PMID: 32879660 DOI: 10.4251/wjgo.v12.i8.791] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 53] [Article Influence: 26.5] [Reference Citation Analysis]
500 Mehta R, Lam-Chung CE, Hinojosa-Amaya JM, Roldán-Sarmiento P, Guillen-Placencia MF, Villanueva-Rodriguez G, Juarez-Leon OA, Leon-Domínguez J, Grajales-Gómez M, Ventura-Gallegos JL, León-Suárez A, Gómez-Pérez FJ, Cuevas-Ramos D. High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2020;11:557. [PMID: 32903471 DOI: 10.3389/fendo.2020.00557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
501 Wu Z, Wang Z, Zheng Z, Bi J, Wang X, Feng Q. Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors. Cancer Manag Res 2020;12:7151-64. [PMID: 32848469 DOI: 10.2147/CMAR.S256723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
502 Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, Tarter Z, Horn M, Weiss H, Oates E, Evers BM, Anthony L. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget 2020;11:3061-8. [PMID: 32850010 DOI: 10.18632/oncotarget.27695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
503 Walter MA, Spanjol M, Kollár A, Bütikofer L, Gloy VL, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Kaderli RM. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
504 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
505 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
506 Caton MT Jr, Shinagare AB, Lee B, Tirumani SH. Optimization of timing of hepatocellular phase imaging after gadoxetate disodium injection for evaluation of patients with neuroendocrine tumor. Abdom Radiol (NY) 2020;45:2358-69. [PMID: 32270259 DOI: 10.1007/s00261-020-02515-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Tanaka M, Heckler M, Mihaljevic AL, Probst P, Klaiber U, Heger U, Schimmack S, Büchler MW, Hackert T. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1614-24. [PMID: 32720049 DOI: 10.1245/s10434-020-08850-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
508 Barat M, Cottereau AS, Kedra A, Dermine S, Palmieri LJ, Coriat R, Dautry R, Tselikas L, Soyer P, Dohan A. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020;9:E2302. [PMID: 32698459 DOI: 10.3390/jcm9072302] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
509 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
510 Krug S, Weissbach J, Blank A, Perren A, Haybaeck J, Fendrich V, Rinke A, Gress TM, Rosendahl J, Michl P. CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E1957. [PMID: 32707646 DOI: 10.3390/cancers12071957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
511 Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ Open 2020;10:e034393. [PMID: 32690499 DOI: 10.1136/bmjopen-2019-034393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
512 Inoue Y, Horie H, Homma Y, Sadatomo A, Tahara M, Koinuma K, Yamaguchi H, Mimura T, Kihara A, Lefor AK, Sata N. Goblet cell carcinoid of the rectum: a case report. Surg Case Rep 2020;6:174. [PMID: 32683504 DOI: 10.1186/s40792-020-00937-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
513 Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. Lung Cancer (Auckl) 2020;11:41-52. [PMID: 32753993 DOI: 10.2147/LCTT.S249928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
514 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
515 Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Sci Rep 2020;10:10943. [PMID: 32616904 DOI: 10.1038/s41598-020-68071-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
516 Basu S, Parghane RV, Naik C. Clinical efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A "not-so-promising" result compared to GEP-NETs. World J Nucl Med 2020;19:205-10. [PMID: 33354174 DOI: 10.4103/wjnm.WJNM_21_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
517 Ali AS, Perren A, Lindskog C, Welin S, Sorbye H, Grönberg M, Janson ET. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Sci Rep 2020;10:10639. [PMID: 32606315 DOI: 10.1038/s41598-020-67670-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
518 Tran CG, Scott AT, Li G, Sherman SK, Ear PH, Howe JR. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling. Surgery 2021;169:155-61. [PMID: 32611516 DOI: 10.1016/j.surg.2020.04.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
519 Xia Y, Zhang L, Wu H, Qiao L, Xia L. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review. J Int Med Res 2020;48:300060520932114. [PMID: 32589085 DOI: 10.1177/0300060520932114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
520 Wang XY, Chai NL, Linghu EQ, Qiu ST, Li LS, Zou JL, Xiang JY, Li XX. The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection. BMC Gastroenterol 2020;20:200. [PMID: 32586282 DOI: 10.1186/s12876-020-01340-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
521 Akın Telli T, Esin E, Yalçın Ş. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan Med J 2020;37:281-6. [PMID: 32573179 DOI: 10.4274/balkanmedj.galenos.2020.2020.1.126] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
522 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
523 Armstrong EA, Beal EW, Lopez-aguiar AG, Poultsides G, Cannon JG, Rocha F, Crown A, Barrett J, Ronnkleiv-kelly S, Fields RC, Krasnick BA, Idrees K, Smith PM, Nathan H, Beems MV, Maithel SK, Schmidt CR, Pawlik TM, Dillhoff M. Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. The American Surgeon 2019;85:1334-40. [DOI: 10.1177/000313481908501225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
524 Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, Hong SM, Ryoo BY, Ryu JS. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020;10:63. [PMID: 32542576 DOI: 10.1186/s13550-020-00651-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
525 Warsinggih, Liliyanto, Prihantono, Ariani GDW, Faruk M. Colorectal neuroendocrine tumors: A case series. Int J Surg Case Rep 2020;72:411-7. [PMID: 32563832 DOI: 10.1016/j.ijscr.2020.06.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
526 Hanif A, Lee S, Gupta M, Chander A, Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood K, Qiu J, Yendamuri S, Iyer R. Exploring the role of survivin in neuroendocrine neoplasms. Oncotarget 2020;11:2246-58. [PMID: 32577168 DOI: 10.18632/oncotarget.27631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
527 Chen Y, Ohki R. p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. Int J Mol Sci 2020;21:E4098. [PMID: 32521808 DOI: 10.3390/ijms21114098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
528 Liu Q, Polydorides AD. Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine. Mod Pathol 2020;33:2318-29. [PMID: 32514164 DOI: 10.1038/s41379-020-0585-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
529 Kleinschmidt TK, Christein J. Neuroendocrine carcinoma of the ampulla of Vater: a case report, review and recommendations. J Surg Case Rep 2020;2020:rjaa119. [PMID: 32537123 DOI: 10.1093/jscr/rjaa119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
530 Mehlis K, Witte J, Surmann B, Kudlich M, Apostolidis L, Walther J, Jäger D, Greiner W, Winkler EC. The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients. BMC Cancer 2020;20:529. [PMID: 32503459 DOI: 10.1186/s12885-020-07028-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
531 Pellat A, Coriat R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. J Clin Med. 2020;9. [PMID: 32492939 DOI: 10.3390/jcm9061677] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
532 Kniepeiss D, Schemmer P. Transplantation bei Lebermetastasen neuroendokriner Tumoren – Heilung oder Palliation? J Klin Endokrinol Stoffw 2020;13:54-58. [DOI: 10.1007/s41969-019-00087-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
533 Medaer E, Verslype C, Van Cutsem E, Dekervel J, Clement PM, Nackaerts K, Laenen A, Gheysens O, Goffin K, Jentjens S, Van Laere K, Deroose CM. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT. Acta Oncol 2020;59:644-51. [PMID: 32036716 DOI: 10.1080/0284186X.2020.1723161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
534 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
535 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol. 2020;11:601-608. [PMID: 32655939 DOI: 10.21037/jgo.2019.11.03] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
536 Memeh KO, Vaghaiwalla T, Keutgen XM. Surgical treatment of non-functioning pancreatic neuroendocrine tumors: current controversies and challenges. Journal of Pancreatology 2020;3:51-8. [DOI: 10.1097/jp9.0000000000000047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging 2021;48:152-60. [PMID: 32472437 DOI: 10.1007/s00259-020-04873-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
538 Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A; NIKE group. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 2020;69:441-50. [PMID: 32468269 DOI: 10.1007/s12020-020-02331-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
539 Vinagre J, Pinheiro J, Martinho O, Reis RM, Preto J, Soares P, Lopes JM. A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms-Granting a Positive Outcome. Cancers (Basel) 2020;12:E1357. [PMID: 32466539 DOI: 10.3390/cancers12061357] [Reference Citation Analysis]
540 Kimura T, Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kofunato Y, Kimura T, Yamada S, Hashimoto Y, Marubashi S, Hikichi T, Ohira H. Pancreatic Neuroendocrine Neoplasm Invading the Entire Main Pancreatic Duct Diagnosed by a Preoperative Endoscopic Biopsy. Intern Med 2020;59:1991-6. [PMID: 32448838 DOI: 10.2169/internalmedicine.4546-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
541 Daşiran MF, Akbaş A. Management of gastric neuroendocrine tumors. Anadolu Kliniği Tıp Bilimleri Dergisi 2020. [DOI: 10.21673/anadoluklin.687259] [Reference Citation Analysis]
542 Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 2020;12:E1437. [PMID: 32429294 DOI: 10.3390/nu12051437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
543 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
544 Kang A, Adamic B, Cooper CA, Paner GP, Werntz RP. Transurethral resection and surveillance of a well-differentiated neuroendocrine tumor in a ileal neobladder. Urol Case Rep 2020;32:101255. [PMID: 32477878 DOI: 10.1016/j.eucr.2020.101255] [Reference Citation Analysis]
545 Sonoda A, Yamashita YI, Kondo T, Hayashi H, Imai K, Higashi T, Yamamura K, Yamao T, Hashimoto D, Baba H. Clinicopathological features and menin expression of pancreatic neuroendocrine neoplasm associated with multiple endocrine neoplasia type 1. J Hepatobiliary Pancreat Sci 2020;27:984-91. [PMID: 32278331 DOI: 10.1002/jhbp.739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
546 Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget 2020;11:1749-57. [PMID: 32477464 DOI: 10.18632/oncotarget.27588] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
547 Gelsomino F, Casadei-Gardini A, Caputo F, Rossi G, Bertolini F, Petrachi T, Spallanzani A, Pettorelli E, Kaleci S, Luppi G. mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. Cancers (Basel) 2020;12:E1201. [PMID: 32397669 DOI: 10.3390/cancers12051201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
548 Kudsi OY, Chang K, Bou-Ayash N. Robotic approach to delayed anastomotic leakage after ileocaecectomy for a neuroendocrine tumour - a video vignette. Colorectal Dis 2020;22:1470. [PMID: 32372480 DOI: 10.1111/codi.15108] [Reference Citation Analysis]
549 Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer 2019;50:816-23. [PMID: 30121904 DOI: 10.1007/s12029-018-0160-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
550 Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol 2020;27:114-63. [PMID: 32205473 DOI: 10.1097/PAP.0000000000000256] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
551 Hong X, Qiao S, Li F, Wang W, Jiang R, Wu H, Chen H, Liu L, Peng J, Wang J, Jia C, Liang X, Dai H, Jiang J, Zhang T, Liao Q, Dai M, Cong L, Han X, Guo D, Liang Z, Li D, Zheng Z, Ye C, Li S, Zhao Y, Wu K, Wu W. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut 2020;69:877-87. [PMID: 31462556 DOI: 10.1136/gutjnl-2018-317233] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
552 Sharma N, Kumar G, Sahai P, Yadav HP. Epidemiologic Study of Patients Registered in Oncology Unit at a Hepatobiliary Tertiary Care Center in India. Indian Journal of Medical and Paediatric Oncology 2020;41:358-367. [DOI: 10.4103/ijmpo.ijmpo_196_18] [Reference Citation Analysis]
553 He H, Guo W, Song P, Liu L, Zhang G, Wang Y, Qiu B, Tan F, Xue Q, Gao S. Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection. Ann Transl Med 2020;8:630. [PMID: 32566567 DOI: 10.21037/atm-19-4476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
554 Samanta STN, Mehta SPB, Patel TS, Jetly DH. Clinicopathological Study of 100 Cases of Neuroendocrine Neoplasms of the Gastroenteropancreatic System: A Tertiary Cancer Center Experience. Indian Journal of Medical and Paediatric Oncology 2020;41:340-344. [DOI: 10.4103/ijmpo.ijmpo_217_18] [Reference Citation Analysis]
555 Slashchuk K, Rumyantsev P, Degtyarev M, Serzhenko S, Baranova O, Trukhin A, Sirota Y. Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd. Medical Radiology and radiation safety 2020;65:44-49. [DOI: 10.12737/1024-6177-2020-65-2-44-49] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
556 Quevedo R, Spreafico A, Bruce J, Danesh A, El Ghamrasni S, Giesler A, Hanna Y, Have C, Li T, Yang SYC, Zhang T, Asa SL, Haibe-Kains B, Krzyzanowska M, Smith AC, Singh S, Siu LL, Pugh TJ. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Med 2020;12:38. [PMID: 32345369 DOI: 10.1186/s13073-020-00730-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
557 Zhang Z, Mäkinen N, Kasai Y, Kim GE, Diosdado B, Nakakura E, Meyerson M. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer 2020;59:535-9. [PMID: 32291827 DOI: 10.1002/gcc.22850] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
558 Chiramel J, Almond R, Slagter A, Khan A, Wang X, Lim KHJ, Frizziero M, Chakrabarty B, Minicozzi A, Lamarca A, Mansoor W, Hubner RA, Valle JW, McNamara MG. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. World J Clin Oncol 2020; 11(4): 205-216 [PMID: 32355642 DOI: 10.5306/wjco.v11.i4.205] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
559 VanDerslice J, Taddie MC, Curtin K, Miller C, Yu Z, Hemmert R, Cannon-Albright LA, Neklason DW. Early life exposures associated with risk of small intestinal neuroendocrine tumors. PLoS One 2020;15:e0231991. [PMID: 32324813 DOI: 10.1371/journal.pone.0231991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
560 Pan J, Bao Q, Enders G. The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor. Front Oncol 2020;10:546. [PMID: 32373532 DOI: 10.3389/fonc.2020.00546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
561 Duan X, Zhao M, Zhang S, Xu Z, Mi L, Shi J, Ma X, Liu Y, Li N, Yin X, Han X, Han G, Wang J, Xu J, Yin F. Effects of tumor distance from anal verge on survival outcomes for rectal NENs and lymphatic metastasis risk score for colorectal NENs. Int J Colorectal Dis 2020;35:1255-64. [PMID: 32314191 DOI: 10.1007/s00384-020-03596-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
562 Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol 2020;11:508. [PMID: 32351498 DOI: 10.3389/fimmu.2020.00508] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 18.5] [Reference Citation Analysis]
563 Nishio M, Hirasawa K, Ozeki Y, Sawada A, Ikeda R, Fukuchi T, Kobayashi R, Makazu M, Sato C, Maeda S. Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors. Ann Gastroenterol 2020;33:265-71. [PMID: 32382229 DOI: 10.20524/aog.2020.0477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
564 Isyangulova AZ, Khasanov RS, Enikeev RF. Targeted therapy for gastrointestinal and pancreatic neuroendocrine tumors. Malignant Tumours 2020;9:49-58. [DOI: 10.18027/2224-5057-2019-9-4-49-58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
565 de Hosson LD, Takkenkamp TJ, Kats-Ugurlu G, Bouma G, Bulthuis M, de Vries EGE, van Faassen M, Kema IP, Walenkamp AME. Neuroendocrine tumours and their microenvironment. Cancer Immunol Immunother 2020;69:1449-59. [PMID: 32270230 DOI: 10.1007/s00262-020-02556-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
566 Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Miserocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. Front Oncol 2020;10:414. [PMID: 32318336 DOI: 10.3389/fonc.2020.00414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
567 Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, del Carmen Mallón Araujo M, del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524 [PMID: 32308351 DOI: 10.3748/wjg.v26.i13.1513] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
568 Trikalinos NA, Tan BR, Amin M, Liu J, Govindan R, Morgensztern D. Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014. BMC Endocr Disord 2020;20:44. [PMID: 32245472 DOI: 10.1186/s12902-020-0525-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
569 Aversa JG, De Abreu FB, Yano S, Xi L, Hadley DW, Manoli I, Raffeld M, Sadowski SM, Nilubol N. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report. BMC Cancer 2020;20:256. [PMID: 32228502 DOI: 10.1186/s12885-020-06723-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
570 Shi Z, Zhang M, Yang W, Xu J. Markedly Elevated HE4 in Hepatic Neuroendocrine Neoplasm: A Report of Two Cases and Literature Review. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.101016] [Reference Citation Analysis]
571 Trikalinos NA, Chatterjee D, Lee J, Liu J, Williams G, Hawkins W, Hammill C. Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Ann Surg Oncol 2020;27:3542-50. [PMID: 32206954 DOI: 10.1245/s10434-020-08377-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
572 Contractor T, Harris CR. Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors. Oncogenesis 2020;9:37. [PMID: 32198354 DOI: 10.1038/s41389-020-0221-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
573 Dikmen K, Kerem M. Stage predictivity of neutrophil/lymphocyte and platelet/lymphocyte ratios in pancreatic neuroendocrine tumors. Turk J Surg 2020;36:1-8. [PMID: 32637869 DOI: 10.5578/turkjsurg.4375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
574 Wang LF, Lin L, Wang MJ, Li Y. The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis. Medicine (Baltimore) 2020;99:e19304. [PMID: 32150065 DOI: 10.1097/MD.0000000000019304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
575 Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg 2019;270:422-33. [PMID: 31283562 DOI: 10.1097/SLA.0000000000003461] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 16.0] [Reference Citation Analysis]
576 Niu C, Wang S, Guan Q, Ren X, Ji B, Liu Y. Neuroendocrine tumors of the gallbladder. Oncol Lett 2020;19:3381-8. [PMID: 32269610 DOI: 10.3892/ol.2020.11461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
577 Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol 2020;121:1067-73. [PMID: 32153032 DOI: 10.1002/jso.25896] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
578 Heckert JM, Kipnis ST, Kumar S, Botterbusch S, Alderson A, Bennett B, Creamer C, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. Oncologist 2020;25:572-8. [PMID: 32141667 DOI: 10.1634/theoncologist.2019-0743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
579 Garg H, Kaushal S, Nayak B, Singh P, Ramteke P, Sarangi J. Carcinoid tumor masquerading as testicular tumor. Journal of Clinical Urology 2020;13:150-153. [DOI: 10.1177/2051415819876785] [Reference Citation Analysis]
580 Kim S, Marcus R, Wells ML, Sheedy SP, Hansel SL, Bruining DH, Barlow JM, Carter RE, Lee YS, Johnson MP, Fidler JL, Goenka AH, McCollough CH, Fletcher JG. The evolving role of imaging for small bowel neuroendocrine neoplasms: estimated impact of imaging and disease-free survival in a retrospective observational study. Abdom Radiol (NY) 2020;45:623-31. [PMID: 31980866 DOI: 10.1007/s00261-020-02410-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
581 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
582 Yu H, Huang Z, Li M, Wei Y, Zhang L, Yang C, Zhang Y, Song B. Differential Diagnosis of Nonhypervascular Pancreatic Neuroendocrine Neoplasms From Pancreatic Ductal Adenocarcinomas, Based on Computed Tomography Radiological Features and Texture Analysis. Acad Radiol 2020;27:332-41. [PMID: 31495760 DOI: 10.1016/j.acra.2019.06.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
583 Lahner H, Führer D. Neuroendokrine Neoplasien. Onkologe 2020;26:261-269. [DOI: 10.1007/s00761-019-00705-5] [Reference Citation Analysis]
584 Sanchez-Nadales A, Celis-Barreto V, Anampa-Guzman A, Salazar-Leon M, Contreras-Chavez P. Carcinoid Right Heart Disease. J Med Cases 2020;11:73-6. [PMID: 34434367 DOI: 10.14740/jmc3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
585 Sirohi B, Barreto SG, Shrikhande SV, Bhandare M, Bal M, Chacko RT, Bhatia V, Basu S, Thulkar S, Kaur T, Dhaliwal RS, Rath GK. Indian Council of Medical Research Consensus Document for the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Indian Journal of Medical and Paediatric Oncology 2020;41:166-172. [DOI: 10.4103/ijmpo.ijmpo_165_19] [Reference Citation Analysis]
586 Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med 2020;34:244-53. [PMID: 32114682 DOI: 10.1007/s12149-020-01440-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
587 Mogl MT, Dobrindt EM, Buschermöhle J, Bures C, Pratschke J, Amthauer H, Wetz C, Jann H. Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis. Visc Med 2020;36:20-7. [PMID: 32110653 DOI: 10.1159/000505500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
588 Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A. 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. J Nucl Med 2020;61:1491-7. [PMID: 32111685 DOI: 10.2967/jnumed.119.240143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
589 Xu GH, Zou HW, Grossman AB. Difference in survival between right- versus left-sided colorectal neuroendocrine neoplasms. J Zhejiang Univ Sci B 2019;20:933-9. [PMID: 31595730 DOI: 10.1631/jzus.B1900210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
590 Yan S, Wang Y, Chen X, Zhang Y, Huang Z, Zhao J, Zhou J, Li Z, Bi X, Luo Z, Cai J, Zhao H. Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching. Cancer Manag Res 2020;12:1437-46. [PMID: 32161496 DOI: 10.2147/CMAR.S227501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
591 Barachini O, Bernt R, Mirzaei S, Pirich C, Hergan K, Zandieh S. The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract. BMC Med Imaging 2020;20:22. [PMID: 32093632 DOI: 10.1186/s12880-020-00424-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
592 Pettersson O, Fröss-Baron K, Crona J, Sundin A. Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. Front Oncol 2020;10:193. [PMID: 32154181 DOI: 10.3389/fonc.2020.00193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
593 Iwamoto M, Gotoda T, Noda Y, Esaki M, Moriyama M, Yoshida N, Takayama T, Kobayashi H, Masuda S. Gastric Neuroendocrine Carcinoma with Rapid Progression. Intern Med 2020;59:1271-6. [PMID: 32074574 DOI: 10.2169/internalmedicine.3961-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
594 Deng BY, Yang M, Wen JY, Hou SZ, Chen Y, Tian BL, Liu XB, Zhang Y. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual. Medicine (Baltimore) 2020;99:e18736. [PMID: 32011453 DOI: 10.1097/MD.0000000000018736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
595 Omori S, Harada N, Toshima T, Takeishi K, Itoh S, Ikegami T, Yoshizumi T, Mori M. Multiple liver metastases originating from synchronous double cancer of neuroendocrine tumor and rectal cancer: a case report. Surg Case Rep 2020;6:36. [PMID: 32056066 DOI: 10.1186/s40792-020-0800-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Isenberg-Grzeda E, MacGregor M, Matsoukas K, Chow N, Reidy-Lagunes D, Alici Y. Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliat Support Care 2020;18:602-8. [PMID: 32036806 DOI: 10.1017/S147895152000005X] [Reference Citation Analysis]
597 Whitt J, Hong WS, Telange RR, Lin CP, Bibb J, Beebe DJ, Chen H, Jaskula-Sztul R. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors. Cancer Gene Ther 2020;27:898-909. [PMID: 32029905 DOI: 10.1038/s41417-020-0167-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
598 Hussain I, Maharaj K, Prince S. The "numb chin syndrome": A case report. Int J Surg Case Rep 2020;67:157-60. [PMID: 32062124 DOI: 10.1016/j.ijscr.2020.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
599 Huang HF, Jin PP, Yang HJ, Zhang CJ, Zhang X, Wang JS, Yu JJ, Zhang B, Zhang Y, Hu QD. Primary Hepatic Neuroendocrine Tumor Mimicking Ruptured Hepatocellular Carcinoma with AFP Elevation: A Case Report and Literature Review. Onco Targets Ther 2020;13:975-9. [PMID: 32099400 DOI: 10.2147/OTT.S236728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
600 Zhao B, Hollandsworth HM, Lopez NE, Parry LA, Abbadessa B, Cosman BC, Ramamoorthy SL, Eisenstein S. Outcomes for a Large Cohort of Patients with Rectal Neuroendocrine Tumors: an Analysis of the National Cancer Database. J Gastrointest Surg 2021;25:484-91. [PMID: 32016672 DOI: 10.1007/s11605-020-04525-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
601 Ma J, Dercle L, Lichtenstein P, Wang D, Chen A, Zhu J, Piessevaux H, Zhao J, Schwartz LH, Lu L, Zhao B. Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. Acad Radiol 2020;27:e10-8. [PMID: 31151901 DOI: 10.1016/j.acra.2019.02.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
602 Armstrong EA, Beal EW, Shah M, Konda B, Abdel-Misih S, Ejaz A, Dillhoff ME, Pawlik TM, Cloyd JM. Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection. Hepatobiliary Surg Nutr 2020;9:1-12. [PMID: 32140474 DOI: 10.21037/hbsn.2019.06.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
603 Patanè E, Sgardello SD, Guendil B, Fournier I, Abbassi Z. Unexpected Finding of a Small Intestinal Neuroendocrine Tumor: A Case Report and Literature Review. Am J Case Rep 2020;21:e917759. [PMID: 31988272 DOI: 10.12659/AJCR.917759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
604 Kunikowska J, Zemczak A, Kołodziej M, Gut P, Łoń I, Pawlak D, Mikołajczak R, Kamiński G, Ruchała M, Kos-Kudła B, Królicki L. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging 2020;47:922-33. [PMID: 31980909 DOI: 10.1007/s00259-020-04690-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
605 Temraz S, Haidar M, Assi R, Hakim A, Jabra E, Charafeddine M, Halabi IE, Mukherji D, Shamseddine A. Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center in Lebanon. Ann Cancer Res Therap 2020;28:9-15. [DOI: 10.4993/acrt.28.9] [Reference Citation Analysis]
606 Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2020;26:2011-21. [PMID: 31937620 DOI: 10.1158/1078-0432.CCR-19-2884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
607 Yumoto S, Miyamoto Y, Akiyama T, Kiyozumi Y, Eto K, Hiyoshi Y, Nagai Y, Iwatsuki M, Baba Y, Iwagami S, Yoshida N, Baba H. Synchronous NET and colorectal cancer development: a case report. Surg Case Rep 2020;6:10. [PMID: 31919616 DOI: 10.1186/s40792-020-0777-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Navin PJ, Yang JD, Torbenson MS, Venkatesh SK. Rare Liver Tumors. Evaluation and Management of Liver Masses 2020. [DOI: 10.1007/978-3-030-46699-2_8] [Reference Citation Analysis]
609 Haug A. Nuclear Medicine Imaging Techniques of the Neuroendocrine System. Clinical Nuclear Medicine 2020. [DOI: 10.1007/978-3-030-39457-8_13] [Reference Citation Analysis]
610 Hain E, Gharios J, Sindayigaya R, Gaujoux S. Quand et avec quelles conséquences opérer une tumeur neuroendocrine du pancréas ou du grêle ? Oncol 2020. [DOI: 10.3166/onco-2019-0048] [Reference Citation Analysis]
611 Weissferdt A. Neuroendocrine Tumors of the Mediastinum. Diagnostic Thoracic Pathology 2020. [DOI: 10.1007/978-3-030-36438-0_29] [Reference Citation Analysis]
612 Testoni SGG, Healey AJ, Dietrich CF, Arcidiacono PG. Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. Endosc Ultrasound 2020;9:83-100. [PMID: 32295966 DOI: 10.4103/eus.eus_74_19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
613 Taggart MW, Foo WC, Lee SM. Tumors of the Gastrointestinal System Including the Pancreas. Oncological Surgical Pathology 2020. [DOI: 10.1007/978-3-319-96681-6_12] [Reference Citation Analysis]
614 de Mestier L, Hentic O, Ruszniewski P. Pancreas; Endocrine Tumors. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65868-3] [Reference Citation Analysis]
615 Horacio A. Chilean experience using “Theranostics” for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE. Arch Clin Gastroenterol 2020. [DOI: 10.17352/2455-2283.000076] [Reference Citation Analysis]
616 Palaiodimos L, Mahato P, Gershon A, Faillace RT. Less Recognized Conditions Associated With PFO. Patent Foramen Ovale Closure for Stroke, Myocardial Infarction, Peripheral Embolism, Migraine, and Hypoxemia 2020. [DOI: 10.1016/b978-0-12-816966-7.00013-0] [Reference Citation Analysis]
617 Sellers MM, Greenstein AJ. Cancer of the Small Bowel. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00073-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Xu J, Cui Y, Huang X, Meng Y, Xin J, Cheng Y. Radical Operation and Everolimus Therapy for Rectal Neuroendocrine Tumor with Liver Metastases: A Case Report with Review of the Literature. CRCM 2020;09:275-281. [DOI: 10.4236/crcm.2020.99039] [Reference Citation Analysis]
619 Larici AR, Cicchetti G, D’ambra G, D’abronzo R, del Ciello A, Calandriello L, Farchione A, Manfredi R, Rindi G. Pulmonary Neuroendocrine Neoplasms. The Thorax 2020. [DOI: 10.1007/978-3-030-27233-3_5] [Reference Citation Analysis]
620 Navin PJ, Welle CL, Wells ML, Venkatesh SK. Computed Tomography (CT). Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65979-2] [Reference Citation Analysis]
621 Wang R, Tuerdi Z, Bi Y, Pan F, Zhang Z, Yang W, Duiyimuhan G. Secondary Hypertension of Other Type. Secondary Hypertension 2020. [DOI: 10.1007/978-981-15-0591-1_19] [Reference Citation Analysis]
622 Seki K, Mori K, Takeuchi H, Ito R, Kubo K, Kobayashi T, Ando S. A Case of Multiple Neuroendocrine Tumors of the Ileum with Nine Tumors Discovered due to Intestinal Obstruction. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2020;81:2260-2267. [DOI: 10.3919/jjsa.81.2260] [Reference Citation Analysis]
623 Kudo T, Nojiri K, Ohya H, Mogaki M, Masui H, Tsura Y, Nagahori K. A Case Report of Resection of Liver Tumor Considerd to Have Developed from Metastases of Pancreatic Gastrinoma 13 Years after Primary Resection. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2020;81:1871-1876. [DOI: 10.3919/jjsa.81.1871] [Reference Citation Analysis]
624 Sartori S, Di Vece F, Tombesi P, Pacella CM. Liver Neuroendocrine Metastases Laser Ablation. Image-guided Laser Ablation 2020. [DOI: 10.1007/978-3-030-21748-8_14] [Reference Citation Analysis]
625 党 智. Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System. ACM 2020;10:2444-2450. [DOI: 10.12677/acm.2020.1011369] [Reference Citation Analysis]
626 Sherf S, Yu R. Gut and Pancreatic Neuroendocrine Tumors in Pregnancy and Lactation. Maternal-Fetal and Neonatal Endocrinology 2020. [DOI: 10.1016/b978-0-12-814823-5.00024-6] [Reference Citation Analysis]
627 Lambregts DMJ, Giammarile F. Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. Imaging and Interventional Radiology for Radiation Oncology 2020. [DOI: 10.1007/978-3-030-38261-2_25] [Reference Citation Analysis]
628 O’donohoe RL, Stedman B. Transcatheter Embolization of Liver Metastases. Image-Guided Interventions 2020. [DOI: 10.1016/b978-0-323-61204-3.00035-x] [Reference Citation Analysis]
629 Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. ERKRANKUNGEN DER ATMUNGSORGANE. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50010-3] [Reference Citation Analysis]
630 Lepage C. Épidémiologie des tumeurs neuroendocrines intestinales. Oncol 2020. [DOI: 10.3166/onco-2019-0051] [Reference Citation Analysis]
631 Hsieh JC, Chen GY, Jhou DD, Chou WC, Yeh CN, Hwang TL, Lin HC, Chu HC, Wang HM, Yen TC, Chen JS, Wu MH. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors. Sci Rep 2019;9:19917. [PMID: 31882775 DOI: 10.1038/s41598-019-56539-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
632 Majala S, Seppänen H, Kemppainen J, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Mustonen H, Vesterinen T, Arola J, Kauhanen S. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT. EJNMMI Res 2019;9:116. [PMID: 31872324 DOI: 10.1186/s13550-019-0585-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
633 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
634 Windmöller BA, Greiner JFW, Förster C, Wilkens L, Mertzlufft F, Schulte Am Esch J, Kaltschmidt B, Kaltschmidt C, Beshay M. A typical carcinoid of the lung - a case report with pathological correlation and propagation of the cancer stem cell line BKZ1 with synaptophysin expression. Medicine (Baltimore) 2019;98:e18174. [PMID: 31804333 DOI: 10.1097/MD.0000000000018174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
635 Kurita Y, Hara K, Kuwahara T, Mizuno N, Okuno N, Haba S, Okuno M, Natsume S, Senda Y, Kubota K, Nakajima A, Niwa Y, Shimizu Y. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol 2020;55:543-52. [PMID: 31858231 DOI: 10.1007/s00535-019-01655-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
636 Ono H, Kudo A, Akahoshi K, Ogura T, Ogawa K, Ban D, Tanaka S, Tanabe M. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2020;146:793-9. [PMID: 31844980 DOI: 10.1007/s00432-019-03109-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
637 Cai W, Ge W, Hu H, Mao J. Rectal NETs and rectosigmoid junction NETs may need to be treated differently. Cancer Med 2020;9:971-9. [PMID: 31840409 DOI: 10.1002/cam4.2779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
638 Alekberzade AV, Krylov NN, Lipnitskiy EM, Shakhbazov RO, Azari F. [Gastric neuroendocrine tumors]. Khirurgiia (Mosk) 2019;:111-20. [PMID: 31825351 DOI: 10.17116/hirurgia2019121111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
639 Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O. Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method. J Med Imaging (Bellingham) 2020;7:012704. [PMID: 31824983 DOI: 10.1117/1.JMI.7.1.012704] [Reference Citation Analysis]
640 Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Res Protoc 2019;8:e14361. [PMID: 31793892 DOI: 10.2196/14361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
641 Masciale V, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Morandi U, Dominici M, Aramini B. Cancer stem-neuroendocrine cells in an atypical carcinoid case report. Transl Lung Cancer Res. 2019;8:1157-1162. [PMID: 32010593 DOI: 10.21037/tlcr.2019.12.07] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
642 Lin Z, Wang H, Zhang Y, Li G, Pi G, Yu X, Chen Y, Jin K, Chen L, Yang S, Zhu Y, Wu G, Chen J, Zhang T. Development and Validation of a Prognostic Nomogram to Guide Decision-Making for High-Grade Digestive Neuroendocrine Neoplasms. Oncologist 2020;25:e659-67. [PMID: 32297441 DOI: 10.1634/theoncologist.2019-0566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
643 Gao H, Cheng Y, Chen Y, Luo F, Shao Y, Sun Z, Bai C. The expression of versican and its role in pancreatic neuroendocrine tumors. Pancreatology 2020;20:142-7. [PMID: 31771905 DOI: 10.1016/j.pan.2019.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
644 Kurman JS, Pastis NJ, Murgu SD. Photodynamic Therapy and Its Use in Lung Disease. Curr Pulmonol Rep 2019;8:215-21. [DOI: 10.1007/s13665-019-00241-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
645 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
646 Mirzaei S, Revheim ME, Raynor W, Zehetner W, Knoll P, Zandieh S, Alavi A. 64Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors. Oncol Ther 2020;8:125-31. [PMID: 32700066 DOI: 10.1007/s40487-019-00104-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
647 Zaidi MY, Lopez-Aguiar AG, Dillhoff M, Beal E, Poultsides G, Makris E, Rocha F, Crown A, Idrees K, Marincola Smith P, Nathan H, Beems M, Abbott D, Barrett JR, Fields RC, Davidson J, Cardona K, Maithel SK. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg. 2019;154:134-140. [PMID: 30383112 DOI: 10.1001/jamasurg.2018.3865] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
648 Rossi RE, Invernizzi P, Mazzaferro V, Massironi S. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterol J 2020;8:140-7. [PMID: 32213066 DOI: 10.1177/2050640619890465] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
649 Reeders J, Ashoka Menon V, Mani A, George M. Clinical Profiles and Survival Outcomes of Patients With Well-Differentiated Neuroendocrine Tumors at a Health Network in New South Wales, Australia: Retrospective Study. JMIR Cancer 2019;5:e12849. [PMID: 31746768 DOI: 10.2196/12849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
650 Lesén E, Granfeldt D, Berthon A, Dinet J, Houchard A, Myrenfors P, Björstad Å, Björholt I, Elf AK, Johanson V. Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study. J Cancer 2019;10:6876-87. [PMID: 31839822 DOI: 10.7150/jca.32381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
651 Shinji S, Sasaki N, Yamada T, Koizumi M, Ohta R, Matsuda A, Yokoyama Y, Takahashi G, Hotta M, Hara K, Takeda K, Ueda K, Kuriyama S, Ishiwata T, Ueda Y, Murakami T, Kanazawa Y, Yoshida H. Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor. Cancer Sci 2019;110:3708-17. [PMID: 31648389 DOI: 10.1111/cas.14221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
652 Corten BJGA, Leclercq WKG, Dercksen MW, van den Broek WT, van Zwam PH, Dejong CH, Slooter GD. Paraganglion, a pitfall in diagnosis after regular cholecystectomy. Int J Surg Case Rep 2019;65:205-8. [PMID: 31731083 DOI: 10.1016/j.ijscr.2019.10.042] [Reference Citation Analysis]
653 Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology 2020;76:251-64. [PMID: 31233624 DOI: 10.1111/his.13943] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
654 Kamikihara Y, Tanoue S, Kawahira M, Iwaya H, Arima S, Sasaki F, Nasu Y, Hashimoto S, Kanmura S, Higashi M, Gejima K, Ido A. A case of gallbladder neuroendocrine carcinoma diagnosed preoperatively using somatostatin receptor scintigraphy. Oncol Lett 2020;19:247-54. [PMID: 31897136 DOI: 10.3892/ol.2019.11101] [Reference Citation Analysis]
655 Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 2020;126:792-9. [PMID: 31714595 DOI: 10.1002/cncr.32607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
656 Weikert T, Maas OC, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter AW, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media Mol Imaging 2019;2019:1517208. [PMID: 31787860 DOI: 10.1155/2019/1517208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
657 Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934-946. [PMID: 31707430 DOI: 10.1007/s00259-019-04567-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 19.3] [Reference Citation Analysis]
658 Dermine S, Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019;8. [PMID: 31703375 DOI: 10.3390/jcm8111907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
659 Ström T, Kozlovacki G, Myrenfors P, Almquist M. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET). Patient Prefer Adherence 2019;13:1799-807. [PMID: 31695341 DOI: 10.2147/PPA.S213472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
660 Bates DDB, de Paula MCF, Horvat N, Sheedy S, Lall C, Kassam Z, Pickhardt P, Lalwani N, Ganeshan D, Petkovska I. Beyond adenocarcinoma: MRI of uncommon rectal neoplasms and mimickers. Abdom Radiol (NY) 2019;44:3581-94. [PMID: 31069482 DOI: 10.1007/s00261-019-02045-9] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
661 Hedenström P. The best approach for sampling of pancreatic neuroendocrine tumors - EUS-FNA or EUS-FNB? Endosc Int Open 2019;7:E1400-2. [PMID: 31682660 DOI: 10.1055/a-0959-6138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
662 Suárez-piñera M, Visa L, Ilzarbe L, Zugazaga A, Poves I, Mestre-fusco A, Iglesias M. PET/CT imaging with somatostatin analogues for the assessment of neuroendocrine tumours, initial experience. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2019;38:382-5. [DOI: 10.1016/j.remnie.2019.02.009] [Reference Citation Analysis]
663 Isyangulova AZ, Khasanov RS, Enikeev RF, Gordiev MG. TREATMENT OF PATIENTS WITH PANCREATIC NEUROENDOCRINE TUMOURS DEPENDING ON THE DIFFERENTIATION GRADE. Sib onkol ž 2019;18:80-85. [DOI: 10.21294/1814-4861-2019-18-5-80-85] [Reference Citation Analysis]
664 Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA). Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. Int J Cancer 2020;146:1316-23. [PMID: 31509608 DOI: 10.1002/ijc.32678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
665 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
666 Kıvrak Salim D, Bayram S, Gömceli İ, Çekin AH, Karaca M, Koçer M, Yıldız M. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals. Turk J Gastroenterol 2019;30:910-6. [PMID: 31625933 DOI: 10.5152/tjg.2019.19168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
667 Dayan A, Ricci C, Campana D, Santini D, Fughelli P, Minni F, Nardo B. Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. ACG Case Rep J 2019;6:e00104. [PMID: 31620513 DOI: 10.14309/crj.0000000000000104] [Reference Citation Analysis]
668 Liu Y, Ye S, Zhu Y, He X, Pan J, Chen S, Ye B, Wang L. Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study. J Cancer 2019;10:6349-57. [PMID: 31772667 DOI: 10.7150/jca.27779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
669 Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, Cosenza P, Ricevuto E, Schietroma M, Carlei F; Oncology Network ASL1 Abruzzo. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. BMC Cancer 2019;19:960. [PMID: 31619203 DOI: 10.1186/s12885-019-6214-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
670 Kamei K, Shindoh J, Kiya Y, Matsumoto I, Hashimoto M, Takeyama Y. Conversion surgery after extensive chemotherapy for stage IV mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: clinical implications from the patterns of response and recurrence. Clin J Gastroenterol 2020;13:240-6. [PMID: 31617127 DOI: 10.1007/s12328-019-01053-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
671 Kim SK, Kim SC, Seo SG, Kim HJ, Cho YK, Jeon WK, Kim BI. Gastroenteropancreatic Neuroendocrine Tumor with Hepatic Metastasis Misdiagnosed as Hepatocellular Carcinoma. Korean J Med 2019;94:449-454. [DOI: 10.3904/kjm.2019.94.5.449] [Reference Citation Analysis]
672 Leeds JS, Nayar MK, Bekkali NLH, Wilson CH, Johnson SJ, Haugk B, Darne A, Oppong KW. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1281-7. [PMID: 31579710 DOI: 10.1055/a-0990-9611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
673 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
674 Souquet P, Girard N, Gérinière L, Arpin D. Tumeurs neuro-endocrines broncho-pulmonaires primitives: tumeurs carcinoïdes et carcinomes neuro-endocrines à grandes cellules. Revue des Maladies Respiratoires Actualités 2019;11:298-305. [DOI: 10.1016/s1877-1203(19)30100-4] [Reference Citation Analysis]
675 Mrzljak A, Kocman B, Skrtic A, Furac I, Popic J, Franusic L, Zunec R, Mayer D, Mikulic D. Liver re-transplantation for donor-derived neuroendocrine tumor: A case report. World J Clin Cases 2019; 7(18): 2794-2801 [PMID: 31616694 DOI: 10.12998/wjcc.v7.i18.2794] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
676 Curtin K, Cannon-Albright LA, VanDerslice J, Yu Z, Herget KA, Thota R, Neklason DW. Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah. Cancer Epidemiol Biomarkers Prev 2019;28:1998-2004. [PMID: 31558509 DOI: 10.1158/1055-9965.EPI-19-0465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
677 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
678 Wang Z, Jiang W, Zheng L, Yan J, Dai J, Huang C, Zhang Q, Yin Z, Gong X, Zhang Y. Consideration of Age Is Necessary for Increasing the Accuracy of the AJCC TNM Staging System of Pancreatic Neuroendocrine Tumors. Front Oncol 2019;9:906. [PMID: 31608226 DOI: 10.3389/fonc.2019.00906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
679 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
680 Zou J, Chen S, Lian G, Li R, Li Y, Huang K, Chen Y. Prognostic and metastasis-related factors in colorectal neuroendocrine tumors: A cross-sectional study based on the Surveillance, Epidemiology and End Results. Oncol Lett 2019;18:5129-38. [PMID: 31612024 DOI: 10.3892/ol.2019.10876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
681 Santos AP, Castro C, Antunes L, Henrique R, Cardoso MH, Monteiro MP. Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome. J Clin Med 2019;8:E1479. [PMID: 31533348 DOI: 10.3390/jcm8091479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
682 Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One 2019;14:e0221994. [PMID: 31527867 DOI: 10.1371/journal.pone.0221994] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
683 Bundschuh RA, Habacha B, Lütje S, Essler M. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons. J Clin Med 2019;8:E1474. [PMID: 31527438 DOI: 10.3390/jcm8091474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
684 Lee JE, Hong SH, Jung HI, Son MW, Ahn TS, Han SW, Cho JH. Small-cell neuroendocrine carcinoma of the ileum: case report and literature review. BMC Surg 2019;19:135. [PMID: 31510991 DOI: 10.1186/s12893-019-0591-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
685 Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. J Clin Med 2019;8:E1455. [PMID: 31547431 DOI: 10.3390/jcm8091455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
686 Yan T, Wang K, Liu J, Zeng Y, Bie F, Wang G, Du J. Wedge resection is equal to segmental resection for pulmonary typical carcinoid patients at localized stage: a population-based analysis. PeerJ 2019;7:e7519. [PMID: 31565553 DOI: 10.7717/peerj.7519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
687 Kulkarni RS, Anand AS, Parikh SK, Panchal HP, Patel AA, Mehta DP, Patel P. Clinical and epidemiological profile of neuroendocrine tumors: An experience from a regional cancer center from Western India. South Asian J Cancer 2019;8:198-202. [PMID: 31489301 DOI: 10.4103/sajc.sajc_364_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
688 Hussain I, Sarvepalli D, Zafar H, Jehanzeb S, Ullah W. Neuroendocrine Tumor: A Rare, Aggressive Tumor of the Gallbladder. Cureus 2019;11:e5571. [PMID: 31695990 DOI: 10.7759/cureus.5571] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
689 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14: 471-482. [PMID: 30096273 DOI: 10.1200/jop.18.00135] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
690 Mapelli P, Ironi G, Fallanca F, Partelli S, Muffatti F, Andreasi V, Gianolli L, Falconi M, De Cobelli F, Picchio M. 68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. Clin Transl Imaging 2019;7:363-71. [DOI: 10.1007/s40336-019-00341-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
691 Cen D, Liu H, Wan Z, Lin Z, Wang Y, Xu J, Liang Y. Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect 2019;8:1273-81. [PMID: 31398710 DOI: 10.1530/EC-19-0124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
692 Jiang S, Han X, Dong D, Zhao R, Ren L, Liu Z, Yang X, Liu H, Dong Y, Han W. Prognostic value of negative lymph node count in patients with jejunoileal neuroendocrine tumors. Journal of Bio-X Research 2019;2:125-31. [DOI: 10.1097/jbr.0000000000000045] [Reference Citation Analysis]
693 Gabrielsen J, Girone G, Bennett B, Jung A. Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors. J Adv Pract Oncol 2019;10:646-59. [PMID: 33391850 DOI: 10.6004/jadpro.2019.10.7.2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
694 Lim KHJ, Valle JW, Lamarca A. Unusual skull base metastasis from neuroendocrine tumor: a case report. J Med Case Rep 2019;13:273. [PMID: 31466520 DOI: 10.1186/s13256-019-2214-5] [Reference Citation Analysis]
695 Kanetkar AV, Patkar S, Khobragade KH, Ostwal V, Ramaswamy A, Goel M. Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. J Gastrointest Cancer 2019;50:298-303. [PMID: 29435905 DOI: 10.1007/s12029-018-0070-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
696 Sapalidis K, Kosmidis C, Funtanidou V, Katsaounis A, Barmpas A, Koimtzis G, Mantalobas S, Alexandrou V, Aidoni Z, Koulouris C, Pavlidis E, Giannakidis D, Surlin V, Pantea S, Strambu V, Constantina RO, Amaniti A, Zarogoulidis P, Mogoantă S, Kesisoglou I, Sardeli C. Update on current pancreatic treatments: from molecular pathways to treatment. J Cancer 2019;10:5162-72. [PMID: 31602269 DOI: 10.7150/jca.36300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
697 Naheed S, Holden C, Tanno L, Jaynes E, Cave J, Ottensmeier CH, Pelosi G. The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ Open 2019;9:e031531. [PMID: 31446421 DOI: 10.1136/bmjopen-2019-031531] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
698 Şen O, Türkçapar AG. Finding carcinoid tumor before bariatric surgery. Is preoperative endoscopy necessary? Case report. Int J Surg Case Rep 2019;62:132-4. [PMID: 31499413 DOI: 10.1016/j.ijscr.2019.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Zhang S, Xue Z, Wen J, Wang B, Chu X. [Surgical Resection and Prognosis of Bronchopulmonary Carcinoid]. Zhongguo Fei Ai Za Zhi 2019;22:494-9. [PMID: 31451139 DOI: 10.3779/j.issn.1009-3419.2019.08.03] [Reference Citation Analysis]
700 Sonbol MB, Halfdanarson TR. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Curr Treat Options Oncol. 2019;20:74. [PMID: 31428952 DOI: 10.1007/s11864-019-0670-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
701 Edwards K, de La Portilla L, Mirza FS, Luthra P. PROINSULIN-PREDOMINANT PANCREATIC NEUROENDOCRINE TUMOR-INDUCED HYPOGLYCEMIA AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY. AACE Clin Case Rep 2019;5:e339-43. [PMID: 31967066 DOI: 10.4158/ACCR-2019-0148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
702 Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019;40:506-36. [PMID: 30657883 DOI: 10.1210/er.2018-00160] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 33.7] [Reference Citation Analysis]
703 Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel M, Prasad V. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging 2020;47:881-94. [PMID: 31414209 DOI: 10.1007/s00259-019-04439-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
704 Zhang H, Deng L, Wang X, Wang D, Teng F, Yu J. Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation. J Cancer Res Clin Oncol 2019;145:2605-12. [PMID: 31410604 DOI: 10.1007/s00432-019-03000-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
705 Ogimi T, Sadahiro S, Kamei Y, Chan LF, Miyakita H, Saito G, Okada K, Suzuki T, Kajiwara H. Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer. Oncology 2019;97:294-300. [PMID: 31390635 DOI: 10.1159/000501521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
706 Zhang C, Wu Y, Zhuang H, Li D, Lin Y, Yin Z, Lu X, Hou B, Jian Z. Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection. Cancer Manag Res 2019;11:7345-52. [PMID: 31496796 DOI: 10.2147/CMAR.S200340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
707 Santos AP, Vinagre J, Soares P, Claro I, Sanches AC, Gomes L, Fernandes I, Catarino AL, Preto J, Pereira BD, Marques AP, Rodrigues F, Amaral C, Rocha G, Mellidez JC, Simões H, Lopes JM, Bugalho MJ; On behalf of the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism . Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol 2019;2019:4518742. [PMID: 31467527 DOI: 10.1155/2019/4518742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
708 Moyade P, Vinjamuri S. The heart matters: a review of incidental cardiac uptake on Ga-68 DOTA peptide PET-CT scans. Nucl Med Commun 2019;40:1081-5. [PMID: 31365503 DOI: 10.1097/MNM.0000000000001064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
709 Corsini EM, Mitchell KG, Sceusi EL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Antonoff MB. Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. J Thorac Dis 2019;11:3391-8. [PMID: 31559043 DOI: 10.21037/jtd.2019.08.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
710 Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol 2019;10:645-51. [PMID: 31392045 DOI: 10.21037/jgo.2019.01.33] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
711 Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
712 Won JH, Ryu JK. Complete Remission of Metastatic Duodenal Neuroendocrine Carcinoma Treated with Chemotherapy and Surgical Resection. Korean J Pancreas Biliary Tract 2019;24:121-126. [DOI: 10.15279/kpba.2019.24.3.121] [Reference Citation Analysis]
713 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
714 Yang W, Pham D, Vierra AT, Azam S, Gui D, Yoon JC. Pulmonary embolism as the presenting symptom and a confounder in ACTH-secreting bronchial carcinoid. Endocrinol Diabetes Metab Case Rep 2019;2019. [PMID: 31352698 DOI: 10.1530/EDM-19-0033] [Reference Citation Analysis]
715 Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:2252-9. [PMID: 31338547 DOI: 10.1007/s00259-019-04431-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
716 Hirayama T, Tomioka H, Onozato Y, Takahara N, Marukawa E, Harada H. A case of neuroendocrine carcinoma arising in the floor of the mouth. Jpn J Oral Maxillofac Surg 2019;65:455-460. [DOI: 10.5794/jjoms.65.455] [Reference Citation Analysis]
717 Varas Lorenzo MJ, Munoz Agel F, Abad Belando R, Sanchez-vizcaino Mengual E. Prevalence of Neuroendocrine Tumors in the Gastrointestinal and Hepatobiliary Systems. Ann Colorectal Res 2019;7. [DOI: 10.5812/acr.88004] [Reference Citation Analysis]
718 Kooyker AI, Verbeek WH, van den Berg JG, Tesselaar ME, van Leerdam ME. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. United European Gastroenterol J 2020;8:59-67. [PMID: 32213058 DOI: 10.1177/2050640619865113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
719 Zhang Y, Shang L, Zhang PP, Chen LH, Wang W, Fang C, Qiu M, Feng XY, Zhou L, Zhang M, Tan HY, Qiu XD, Wang H, Lin R, Zhang Q, Zeng YJ, Jin KZ, Yu XJ, Shen L, Chen MH, Li J, Li LP, Chen J. Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. Cancer Med 2019;8:5000-11. [PMID: 31293053 DOI: 10.1002/cam4.2370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
720 Guzman C, Boddhula S, Panneerselvam N, Dodhia C, Hellenthal NJ, Monie D, Monzon JR, Kaufman T. Appendiceal Carcinoid Tumors: Is There a Survival Advantage to Colectomy over Appendectomy? J Gastrointest Surg 2020;24:1149-57. [PMID: 31273553 DOI: 10.1007/s11605-019-04306-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
721 Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, Melstrom L. Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease. Am J Clin Oncol 2018;41:882-7. [PMID: 28763328 DOI: 10.1097/COC.0000000000000392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
722 Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Systemic treatment for lung carcinoids: from bench to bedside. Clin Transl Med 2019;8:22. [PMID: 31273555 DOI: 10.1186/s40169-019-0238-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
723 Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist 2019;24:1384-94. [PMID: 31270268 DOI: 10.1634/theoncologist.2019-0112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
724 Si Y, Kim S, Guenter R, Ou J, Lu Y, Chen K, Zhang J, Whitt J, Carter AM, Bibb JA, Jaskula-sztul R, Markert JM, Zhou L, Chen H, “Margaret” Liu X. Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy.. [DOI: 10.1101/688184] [Reference Citation Analysis]
725 Samsom KG, van Veenendaal LM, Valk GD, Vriens MR, Tesselaar MET, van den Berg JG. Molecular prognostic factors in small-intestinal neuroendocrine tumours. Endocr Connect 2019;8:906-22. [PMID: 31189127 DOI: 10.1530/EC-19-0206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
726 Schimmack S, Yang Y, Felix K, Herbst M, Li Y, Schenk M, Bergmann F, Hackert T, Strobel O. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. Endocr Connect 2019;8:1007-19. [PMID: 31234146 DOI: 10.1530/EC-19-0132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
727 Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med 2019;25:1260-5. [PMID: 31263286 DOI: 10.1038/s41591-019-0493-4] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 28.7] [Reference Citation Analysis]
728 Bernsmeier A, Braun F. Lebertransplantation bei primären Lebertumoren und Lebermetastasen. Gastroenterologe 2019;14:269-281. [DOI: 10.1007/s11377-019-0352-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
729 Kim H, Song KB, Hwang DW, Lee JH, Alshammary S, Kim SC. Time-trend and recurrence analysis of pancreatic neuroendocrine tumors. Endocr Connect 2019;8:1052-60. [PMID: 31252400 DOI: 10.1530/EC-19-0282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
730 Alshammari TF, Hakami RA, Alali MN, AlShammari S, Zayed MA, AlSohaibani MO, Bin Traiki T. A Perforated Colonic Neuroendocrine Tumor with Liver Metastasis: A Case Report and Literature Review. Am J Case Rep 2019;20:920-5. [PMID: 31249283 DOI: 10.12659/AJCR.916288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
731 Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One 2019;14:e0218953. [PMID: 31237925 DOI: 10.1371/journal.pone.0218953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
732 Mahmud N, Tomizawa Y, Stashek K, Katona BW, Ginsberg GG, Metz DC. Endoscopic Resection of Duodenal Carcinoid Tumors: A Single-Center Comparison Between Simple Polypectomy and Endoscopic Mucosal Resection. Pancreas 2019;48:60-5. [PMID: 30451799 DOI: 10.1097/MPA.0000000000001197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
733 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 22.3] [Reference Citation Analysis]
734 Gu D, Hu Y, Ding H, Wei J, Chen K, Liu H, Zeng M, Tian J. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol. 2019;29:6880-6890. [PMID: 31227882 DOI: 10.1007/s00330-019-06176-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
735 Bösch F, Werner J, Angele MK, Guba MO. [Oligometastases of neuroendocrine tumors-extent of surgery]. Chirurg 2018;89:516-22. [PMID: 29876615 DOI: 10.1007/s00104-018-0644-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
736 Bleicher J, Lombardo S, Carbine S, Kapitonov D, Pletneva MA, Mulvihill SJ. Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. J Pancreat Cancer 2019;5:22-5. [PMID: 31236541 DOI: 10.1089/pancan.2019.0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
737 Zhang L, Yang Z, Chen Q, Li M, Zhu X, Wan D, Xie H, Zheng S. Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Oncol Lett 2019;18:1585-96. [PMID: 31423226 DOI: 10.3892/ol.2019.10502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
738 Sandblom V, Ståhl I, Hansson C, Olofsson Bagge R, Forssell-Aronsson E. Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy. Surg Oncol 2019;29:148-56. [PMID: 31196481 DOI: 10.1016/j.suronc.2019.05.002] [Reference Citation Analysis]
739 Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 2019;19:575. [PMID: 31196127 DOI: 10.1186/s12885-019-5794-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
740 Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. J Cancer 2019;10:3140-4. [PMID: 31289584 DOI: 10.7150/jca.30355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
741 Gulpinar B, Peker E, Kul M, Elhan AH, Haliloglu N. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features? Abdom Radiol (NY) 2019;44:2147-55. [PMID: 30863999 DOI: 10.1007/s00261-019-01963-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
742 Kitade H, Ohtsubo K, Hokkoku K, Mori M, Osamura RY, Sakuma H, Nakai M, Yano S. A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Int Cancer Conf J 2019;8:24-8. [PMID: 31149542 DOI: 10.1007/s13691-018-0348-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
743 Matsui S, Kudo A, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tanabe M. Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? J Cancer Res Clin Oncol 2019;145:2097-104. [PMID: 31147832 DOI: 10.1007/s00432-019-02947-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
744 Liu T, Liao J, Dang J, Li G. Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919853673. [PMID: 31191714 DOI: 10.1177/1758835919853673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
745 Farina DA, Krogh KM, Boike JR. Chronic Diarrhea Secondary to Newly Diagnosed VIPoma. Case Rep Gastroenterol 2019;13:225-9. [PMID: 31123451 DOI: 10.1159/000494554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
746 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
747 Song L, Zhai X, Yu S, Ma Y, Wang F, Yu X, Tao S, Lian Y, Yang M, Tao W, Fan Q. Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study. Cancer Med 2019;8:3729-37. [PMID: 31127690 DOI: 10.1002/cam4.2259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
748 Aly RG, Rekhtman N, Li X, Takahashi Y, Eguchi T, Tan KS, Rudin CM, Adusumilli PS, Travis WD. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. J Thorac Oncol 2019;14:1583-93. [PMID: 31121325 DOI: 10.1016/j.jtho.2019.05.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
749 Parra-Medina R, Moreno-Lucero P, Jimenez-Moreno J, Parra-Morales AM, Romero-Rojas A. Neuroendocrine neoplasms of gastrointestinal tract and secondary primary synchronous tumors: A systematic review of case reports. Casualty or causality? PLoS One 2019;14:e0216647. [PMID: 31086397 DOI: 10.1371/journal.pone.0216647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
750 Mei S, Gibbs J, Economos K, Lee YC, Kanis MJ. Clinical comparison between neuroendocrine and endometrioid type carcinoma of the uterine corpus. J Gynecol Oncol 2019;30:e58. [PMID: 31074241 DOI: 10.3802/jgo.2019.30.e58] [Reference Citation Analysis]
751 Oh S, Park JT. Zebrafish model of KRAS-initiated pancreatic endocrine tumor. Anim Cells Syst (Seoul) 2019;23:209-18. [PMID: 31231585 DOI: 10.1080/19768354.2019.1610058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
752 Bordin-Wosk T, Patel SP, Horman SF. GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. J Gen Intern Med 2019;34:1658-61. [PMID: 31062226 DOI: 10.1007/s11606-019-05040-4] [Reference Citation Analysis]
753 Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM, Fottner C. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Front Oncol 2019;9:343. [PMID: 31134150 DOI: 10.3389/fonc.2019.00343] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
754 Barthet M. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumor. Ann Endocrinol (Paris) 2019;80:182-4. [PMID: 31053252 DOI: 10.1016/j.ando.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
755 Sham JG, Gage MM, He J. Contemporary issues in the surgical management of pancreatic neuroendocrine tumours. Surg Pract 2019;23:37-41. [DOI: 10.1111/1744-1633.12349] [Reference Citation Analysis]
756 Chan LL, Chan SL. Systemic treatment of pancreatic neuroendocrine tumors. Surg Pract 2019;23:48-58. [DOI: 10.1111/1744-1633.12351] [Reference Citation Analysis]
757 Padmanabhan N, Ahmed S, Kurian A, Ravishankar P. Unusual and Aggressive Cause of Gall Bladder Mass-Neuroendocrine Tumor. J Gastrointest Cancer 2020;51:307-10. [PMID: 31037470 DOI: 10.1007/s12029-019-00245-6] [Reference Citation Analysis]
758 Fung AK, Chong CC. Surgical strategy for neuroendocrine liver metastases. Surg Pract 2019;23:59-67. [DOI: 10.1111/1744-1633.12364] [Reference Citation Analysis]
759 Garg R, Kumar R, Singh P, Kshetrimayum S. Atypical carcinoid tumor of the lung: A rare entity. Lung India 2019;36:236-8. [PMID: 31031346 DOI: 10.4103/lungindia.lungindia_111_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
760 Kudo A, Tanabe M. Neoadjuvant chemotherapy for pancreatic neuroendocrine tumors with distant metastases. Journal of the Japan Pancreas Society 2019;34:86-91. [DOI: 10.2958/suizo.34.86] [Reference Citation Analysis]
761 Sasano H, Fujishima F, Watanabe H. Changing concepts of pancreatic neuroendocrine neoplasms: From WHO 2010 to WHO 2017. Journal of the Japan Pancreas Society 2019;34:56-62. [DOI: 10.2958/suizo.34.56] [Reference Citation Analysis]
762 You Y, Jang JY, Kim SC, Yoon YS, Park JS, Cho CK, Park SJ, Yang JD, Lee WJ, Hong TH, Ahn KS, Jeong CY, Lee HK, Lee SE, Roh YH, Kim HJ, Kim H, Han IW. Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database. Cancer Res Treat. 2019;51:1639-1652. [PMID: 30999719 DOI: 10.4143/crt.2019.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
763 Raman V, Jawitz OK, Yang CJ, Tong BC, D'Amico TA, Berry MF, Harpole DH Jr. Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Ann Thorac Surg 2019;108:377-83. [PMID: 31004586 DOI: 10.1016/j.athoracsur.2019.03.053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
764 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
765 Zhang P, Li YL, Qiu XD, Luo J, Shi YF, Sun YL, Su F, Qi ZR, Tan HY. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study. World J Surg Oncol 2019;17:66. [PMID: 30975157 DOI: 10.1186/s12957-019-1606-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
766 Han X, Lou W. Concomitant pancreatic neuroendocrine tumors in hereditary tumor syndromes: who, when and how to operate? Journal of Pancreatology 2019;2:48-53. [DOI: 10.1097/jp9.0000000000000016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
767 Wong S, To V, Lam J, Lam A. Metastatic neuroendocrine tumour mimicking endometriosis highlights the importance of excision for tissue diagnosis. Journal of Endometriosis and Pelvic Pain Disorders 2019;11:108-11. [DOI: 10.1177/2284026519838717] [Reference Citation Analysis]
768 Lv Y, Han X, Xu XF, Ji Y, Zhou YH, Sun HC, Zhou J, Fan J, Lou WH, Huang C. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. BMC Cancer 2019;19:335. [PMID: 30961559 DOI: 10.1186/s12885-019-5457-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
769 Chakrabarti D, Qayoom S, Ghosh A, Gupta R. Neuroendocrine carcinoma of the gall bladder in a young lady presenting with upper abdominal heaviness: a common complaint and a rare diagnosis. BMJ Case Rep 2019;12:e229684. [PMID: 30954965 DOI: 10.1136/bcr-2019-229684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
770 Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249-256. [PMID: 30945061 DOI: 10.1007/s00464-019-06759-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
771 Onyemkpa C, Davis A, McLeod M, Oyasiji T. Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile and predictors. J Gastrointest Oncol 2019;10:300-6. [PMID: 31032098 DOI: 10.21037/jgo.2018.11.08] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
772 Lima LL, Parente DB, Batista RV, Araújo AED. Additional value of a dynamic contrast-enhanced study for detection of a small neuroendocrine tumor of the rectum on magnetic resonance imaging. Radiol Bras 2019;52:135-136. [DOI: 10.1590/0100-3984.2017.0150] [Reference Citation Analysis]
773 Broncano J, Alvarado-Benavides AM, Bhalla S, Álvarez-Kindelan A, Raptis CA, Luna A. Role of advanced magnetic resonance imaging in the assessment of malignancies of the mediastinum. World J Radiol 2019; 11(3): 27-45 [PMID: 30949298 DOI: 10.4329/wjr.v11.i3.27] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
774 Uema D, Alves C, Mesquita M, Nuñez JE, Siepmann T, Angel M, Rego JFM, Weschenfelder R, Rocha Filho DR, Costa FP, Barros M, O'Connor JM, Illigens BM, Riechelmann RP. Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study. J Clin Med 2019;8:E405. [PMID: 30909590 DOI: 10.3390/jcm8030405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
775 Feng T, Lv W, Yuan M, Shi Z, Zhong H, Ling S. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. World J Surg Oncol 2019;17:54. [PMID: 30898132 DOI: 10.1186/s12957-019-1597-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
776 Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, Keutgen X. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases. Int J Endocrinol. 2019;2019:9871319. [PMID: 30992703 DOI: 10.1155/2019/9871319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
777 Liu B, Kudo A, Kinowaki Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Akashi T, Tanabe M. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. J Gastroenterol 2019;54:819-28. [PMID: 30863885 DOI: 10.1007/s00535-019-01570-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
778 Rendell MS. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. Drug Des Devel Ther 2019;13:817-24. [PMID: 30880915 DOI: 10.2147/DDDT.S144556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
779 Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest 2019;129:1641-53. [PMID: 30721156 DOI: 10.1172/JCI123049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
780 Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer 2019;26:R157-79. [PMID: 30615596 DOI: 10.1530/ERC-18-0354] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
781 Yu L, Zhao R, Han X, Shou J, You L, Jiang H, Zhou X, Liu Z, Pan H, Han W. Lymph node involvement in pancreatic neuroendocrine tumors: significance as a predictor of survival. Journal of Bio-X Research 2019;2:25-33. [DOI: 10.1097/jbr.0000000000000024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
782 Mahajan S, O'Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. J Nucl Med Radiat Ther 2019;10:395. [PMID: 31057988 DOI: 10.4172/2155-9619.1000395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
783 Wang ZD, Jiao XX, Peng XQ, Liu L, Zhang LF, Zhou L. Clinicopathological characteristics and prognosis of gastric neuroendocrine neoplasms of different clinical classifications. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 267-275 [DOI: 10.11569/wcjd.v27.i4.267] [Reference Citation Analysis]
784 Xu F, Chen K, Lu C, Gu J, Zeng H, Xu Y, Ji Y, Ge D. Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features. Transl Oncol 2019;12:646-55. [PMID: 30818166 DOI: 10.1016/j.tranon.2019.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
785 Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, Senellart H, Heymann MF, Matysiak-Budnik T, Touchefeu Y. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol 2019;10:103-11. [PMID: 30788165 DOI: 10.21037/jgo.2018.09.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
786 Kaliya-Perumal AK, Tan M, Tee SW, Achudan S, Yap WM, Oh JYL. Early post-surgical recurrence of metastatic vertebral neuro-endocrine tumour treated effectively with chemo-radiotherapy. Biomedicine (Taipei) 2019;9:5. [PMID: 30794152 DOI: 10.1051/bmdcn/2019090105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
787 Goto Y, Motoi N. Neuroendocrine Tumor of Lung and Mediastinum: the Updated Pathological Diagnosis and Treatment. JJLC 2019;59:37-45. [DOI: 10.2482/haigan.59.37] [Reference Citation Analysis]
788 Komaç Ö, Bengi G, Sağol Ö, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. World J Gastrointest Oncol 2019; 11(2): 139-152 [PMID: 30788040 DOI: 10.4251/wjgo.v11.i2.139] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
789 Ushigome H, Fukunaga Y, Nagasaki T, Akiyoshi T, Konishi T, Fujimoto Y, Nagayama S, Ueno M. Difficulty of predicting lymph node metastasis on CT in patients with rectal neuroendocrine tumors. PLoS One 2019;14:e0211675. [PMID: 30742649 DOI: 10.1371/journal.pone.0211675] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
790 Belotto M, Crouzillard B, Araujo KO, Peixoto RD. Pancreatic Neuroendocrine Tumors: Surgical Resection. Arq Bras Cir Dig. 2019;32:e1428. [PMID: 30758476 DOI: 10.1590/0102-672020180001e1428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
791 Skertich NJ, Gerard J, Poirier J, Hertl M, Pappas SG, Schadde E, Keutgen XM. Do All Abdominal Neuroendocrine Tumors Require Extended Postoperative VTE Prophylaxis? J Gastrointest Surg. 2019;23:788-793. [PMID: 30671795 DOI: 10.1007/s11605-018-04075-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
792 Wang Z, Cheng S, Zhou F, Han X, Lu X, Sun D, Zhang X. [Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor]. Zhongguo Fei Ai Za Zhi 2019;22:34-9. [PMID: 30674391 DOI: 10.3779/j.issn.1009-3419.2019.01.07] [Reference Citation Analysis]
793 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 112] [Cited by in F6Publishing: 119] [Article Influence: 37.3] [Reference Citation Analysis]
794 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
795 Tirosh A, Mukherjee S, Lack J, Gara SK, Wang S, Quezado MM, Keutgen XM, Wu X, Cam M, Kumar S, Patel D, Nilubol N, Tyagi MV, Kebebew E. Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. Cancer 2019;125:1247-57. [PMID: 30620390 DOI: 10.1002/cncr.31930] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
796 Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1056-65. [PMID: 30606883 DOI: 10.1634/theoncologist.2018-0519] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
797 Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1066-75. [PMID: 30610008 DOI: 10.1634/theoncologist.2018-0520] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
798 Miyagawa K, Nakabayashi Y, Ishihara Y, Todo M, Fuji N. A Case of Streptozocin Monotherapy for Unresectable Duodenal Neuroendocrine Tumor G2. Case Rep Oncol 2019;12:14-21. [DOI: 10.1159/000496017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
799 Tadman M, Martin L. Multiple Endocrine Neoplasia. Advanced Practice in Endocrinology Nursing 2019. [DOI: 10.1007/978-3-319-99817-6_66] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
800 Twickler MTB, Regieli J, Grobben R, Hart EA, Tesselaar ME, Meijer RCA, Chamuleau SAJ, Nathoe HM. Impact of Endocrine Disorders on the Heart. Endocrinology 2019. [DOI: 10.1007/978-3-319-66362-3_3-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
801 Yim KL, Thomas BM, Christian A. Clinical Approaches to the Management of Neuroendocrine Tumours. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_38] [Reference Citation Analysis]
802 Varas-lorenzo M, Cugat E, Capdevila J, Sánchez-vizcaíno Mengual E. Detection of pancreatic neuroendocrine tumors: 23 years of experience. Revista de Gastroenterología de México (English Edition) 2019;84:18-25. [DOI: 10.1016/j.rgmxen.2018.08.001] [Reference Citation Analysis]
803 Tsoli M, Kaltsas G. Carcinoid Syndrome. Encyclopedia of Endocrine Diseases 2019. [DOI: 10.1016/b978-0-12-801238-3.65346-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
804 Romanet P, Goudet P, Barlier A. Multiple Endocrine Neoplasia Type 1. Endocrinology 2019. [DOI: 10.1007/978-3-319-73082-0_8-1] [Reference Citation Analysis]
805 Barry L, Mcfadden DW. Gastrointestinal Carcinoid Tumors. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00080-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
806 Matthaei H, Manekeller S. Palliative Chirurgie hepatobiliärer Tumoren. Palliative Viszeralchirurgie 2019. [DOI: 10.1007/978-3-662-57362-4_20] [Reference Citation Analysis]
807 Steele SR, Wen Y, Kennedy GD. Rare Colorectal Malignancies. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00175-8] [Reference Citation Analysis]
808 Larghi A, Rizzatti G, Rimbaş M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat? Endosc Ultrasound 2019;8:220-6. [PMID: 31249164 DOI: 10.4103/eus.eus_28_19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
809 Parghane RV, Talole S, Basu S. Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J Nucl Med 2019;18:160-70. [PMID: 31040748 DOI: 10.4103/wjnm.WJNM_39_18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
810 Fisher GA. Gastroenteropancreatic Neuroendocrine Tumors. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_16] [Reference Citation Analysis]
811 Srivani G, Dariya B, Farran B, Alam A, Nagaraju GP. Biology of Pancreas and Possible Diseases. Exploring Pancreatic Metabolism and Malignancy 2019. [DOI: 10.1007/978-981-32-9393-9_1] [Reference Citation Analysis]
812 Tadman M, Davies P, Whyand T, Martin L. Neuroendocrine Tumours. Advanced Practice in Endocrinology Nursing 2019. [DOI: 10.1007/978-3-319-99817-6_65] [Reference Citation Analysis]
813 Röcken C. Lyphmknotenmetastasen bei unbekanntem Primärtumor. Pathologie 2019. [DOI: 10.1007/978-3-540-85184-4_29] [Reference Citation Analysis]
814 Bang JY, Rösch T. Endoscopic Ultrasound and Pancreatic Tumors. Endosonography 2019. [DOI: 10.1016/b978-0-323-54723-9.00014-2] [Reference Citation Analysis]
815 Moore AR, Yip VS. Treatment of Neuroendocrine Tumour Disease. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_20] [Reference Citation Analysis]
816 Kutluk MT, Ataş E. Gastrointestinal Cancers in Children. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_18] [Reference Citation Analysis]
817 Ladner DP, Norton JA. Neuroendocrine Tumors of the Pancreas. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00097-2] [Reference Citation Analysis]
818 Kolbanov KI, Pikin OV, Ryabov AB, Glushko VA. Mediastinal tumors: classifications. Onkol Z im P A Gercena 2019;8:471. [DOI: 10.17116/onkolog20198061471] [Reference Citation Analysis]
819 Sakin A, Tambas M, Secmeler S, Can O, Arici S, Yasar N, Geredeli C, Demir C, Cihan S. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pac J Cancer Prev 2018;19:3597-603. [PMID: 30583688 DOI: 10.31557/APJCP.2018.19.12.3597] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
820 Antoniadou F, Korkolis D, Koufopoulos N, Manatakis D, Sakellariou S. A well differentiated neuroendocrine tumor of the jejunum with peritoneal carcinomatosis: A case report. Mol Clin Oncol 2018;9:651-5. [PMID: 30546896 DOI: 10.3892/mco.2018.1734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
821 Sampedro-Núñez M, Serrano-Somavilla A, Adrados M, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Martínez-Hernández R, Martín-Pérez E, Muñoz de Nova JL, Díaz JÁ, García-Centeno R, Caneiro-Gómez J, Abdulkader I, González-Amaro R, Marazuela M. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci Rep 2018;8:17812. [PMID: 30546030 DOI: 10.1038/s41598-018-36129-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
822 Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers (Basel) 2018;10:E510. [PMID: 30545054 DOI: 10.3390/cancers10120510] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
823 Póvoa S, Azevedo D, Marques C, Barroca H, Costa A. Unknown primary large-cell neuroendocrine tumor. Autops Case Rep 2018;8:e2018025. [PMID: 30533401 DOI: 10.4322/acr.2018.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
824 Kang J, Yoo C, Hwang HS, Hong SM, Kim KP, Kim SY, Hong YS, Kim TW, Ryoo BY. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Invest New Drugs 2019;37:763-70. [PMID: 30536151 DOI: 10.1007/s10637-018-0710-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
825 Wang Y, Huang K, Chen J, Luo Y, Zhang Y, Jia Y, Xu L, Chen M, Huang B, Ni D, Li ZP, Feng ST. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media Mol Imaging 2018;2018:6037273. [PMID: 30510495 DOI: 10.1155/2018/6037273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
826 Zhang C, Huang Y, Long J, Yao X, Wang J, Zang S, Qu W, Wang F. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression. Oncol Lett 2019;17:1497-504. [PMID: 30675205 DOI: 10.3892/ol.2018.9795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
827 van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study. Front Endocrinol (Lausanne) 2018;9:740. [PMID: 30564197 DOI: 10.3389/fendo.2018.00740] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
828 Abreu RPNDS. Appendiceal neuroendocrine tumors: approach and treatment. Journal of Coloproctology 2018;38:337-342. [DOI: 10.1016/j.jcol.2018.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
829 Esin E, Oksuzoglu B, Erdur E, Ozgun G, Demirci U. Well differentiated neuroendocrine tumors, a single center experience. Journal of Oncological Sciences 2018;4:119-24. [DOI: 10.1016/j.jons.2018.10.002] [Reference Citation Analysis]
830 Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. Endocr Connect 2018;7:1535-41. [PMID: 30530877 DOI: 10.1530/EC-18-0478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
831 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24:911-920. [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
832 Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, Nervi B, Sánchez C, Galindo H, Ibañez C, Peña J, Balmaceda C, Madrid J, Briones J, Torres J, Nilo F, Guarda FJ, Quintana JC, Orellana P, Mondaca S, Acevedo F, Vicentini D, Cordova-Delgado M, Owen GI, Garrido M. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer 2019;10:3-10. [PMID: 30465145 DOI: 10.1007/s12672-018-0354-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
833 Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 2018;18:1122. [PMID: 30445941 DOI: 10.1186/s12885-018-5057-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
834 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. [PMID: 30519109 DOI: 10.2147/cmar.s174907] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 17.8] [Reference Citation Analysis]
835 Sato K, Toyoshima Y, Moriyama S, Endo Y, Ito T, Ohki E. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study. Cancer Chemother Pharmacol 2019;83:201-7. [PMID: 30413868 DOI: 10.1007/s00280-018-3724-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analy